<?xml version="1.0" encoding="utf-8"?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="2002-05-27" modified="2020-10-07" version="203">
<accession>Q96RI1</accession>
<accession>A1L4K5</accession>
<accession>B7Z412</accession>
<accession>B7ZM06</accession>
<accession>F8VYG8</accession>
<accession>Q8NFP5</accession>
<accession>Q8NFP6</accession>
<accession>Q92943</accession>
<name>NR1H4_HUMAN</name>
<protein>
<recommendedName>
<fullName>Bile acid receptor</fullName>
</recommendedName>
<alternativeName>
<fullName>Farnesoid X-activated receptor</fullName>
</alternativeName>
<alternativeName>
<fullName>Farnesol receptor HRR-1</fullName>
</alternativeName>
<alternativeName>
<fullName>Nuclear receptor subfamily 1 group H member 4</fullName>
</alternativeName>
<alternativeName>
<fullName>Retinoid X receptor-interacting protein 14</fullName>
<shortName>RXR-interacting protein 14</shortName>
</alternativeName>
</protein>
<gene>
<name type="primary">NR1H4</name>
<name type="synonym">BAR</name>
<name type="synonym">FXR</name>
<name type="synonym">HRR1</name>
<name type="synonym">RIP14</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="submission" date="1996-08" db="EMBL/GenBank/DDBJ databases">
<title>The identification of the cDNA coding for HRR-1, a novel human farnesol receptor.</title>
<authorList>
<person name="Papetti M."/>
<person name="Wood N."/>
<person name="Lohmar P.D."/>
<person name="Bowman M.R."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4)</scope>
</reference>
<reference key="2">
<citation type="submission" date="2001-05" db="EMBL/GenBank/DDBJ databases">
<title>Functional analysis of human farnesol receptor (NR1H4) splicing variant.</title>
<authorList>
<person name="Han J.-I."/>
<person name="Bok S.-H."/>
<person name="Jeong T.-S."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3)</scope>
</reference>
<reference key="3">
<citation type="journal article" date="2002" name="Gene" volume="290" first="35" last="43">
<title>Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters.</title>
<authorList>
<person name="Huber R.M."/>
<person name="Murphy K."/>
<person name="Miao B."/>
<person name="Link J.R."/>
<person name="Cunningham M.R."/>
<person name="Rupar M.J."/>
<person name="Gunyuzlu P.L."/>
<person name="Haws T.F. Jr."/>
<person name="Kassam A."/>
<person name="Powell F."/>
<person name="Hollis G.F."/>
<person name="Young P.R."/>
<person name="Mukherjee R."/>
<person name="Burn T.C."/>
</authorList>
<dbReference type="PubMed" id="12062799"/>
<dbReference type="DOI" id="10.1016/s0378-1119(02)00557-7"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2)</scope>
<scope>ALTERNATIVE SPLICING (ISOFORMS 3 AND 4)</scope>
</reference>
<reference key="4">
<citation type="journal article" date="2004" name="Nat. Genet." volume="36" first="40" last="45">
<title>Complete sequencing and characterization of 21,243 full-length human cDNAs.</title>
<authorList>
<person name="Ota T."/>
<person name="Suzuki Y."/>
<person name="Nishikawa T."/>
<person name="Otsuki T."/>
<person name="Sugiyama T."/>
<person name="Irie R."/>
<person name="Wakamatsu A."/>
<person name="Hayashi K."/>
<person name="Sato H."/>
<person name="Nagai K."/>
<person name="Kimura K."/>
<person name="Makita H."/>
<person name="Sekine M."/>
<person name="Obayashi M."/>
<person name="Nishi T."/>
<person name="Shibahara T."/>
<person name="Tanaka T."/>
<person name="Ishii S."/>
<person name="Yamamoto J."/>
<person name="Saito K."/>
<person name="Kawai Y."/>
<person name="Isono Y."/>
<person name="Nakamura Y."/>
<person name="Nagahari K."/>
<person name="Murakami K."/>
<person name="Yasuda T."/>
<person name="Iwayanagi T."/>
<person name="Wagatsuma M."/>
<person name="Shiratori A."/>
<person name="Sudo H."/>
<person name="Hosoiri T."/>
<person name="Kaku Y."/>
<person name="Kodaira H."/>
<person name="Kondo H."/>
<person name="Sugawara M."/>
<person name="Takahashi M."/>
<person name="Kanda K."/>
<person name="Yokoi T."/>
<person name="Furuya T."/>
<person name="Kikkawa E."/>
<person name="Omura Y."/>
<person name="Abe K."/>
<person name="Kamihara K."/>
<person name="Katsuta N."/>
<person name="Sato K."/>
<person name="Tanikawa M."/>
<person name="Yamazaki M."/>
<person name="Ninomiya K."/>
<person name="Ishibashi T."/>
<person name="Yamashita H."/>
<person name="Murakawa K."/>
<person name="Fujimori K."/>
<person name="Tanai H."/>
<person name="Kimata M."/>
<person name="Watanabe M."/>
<person name="Hiraoka S."/>
<person name="Chiba Y."/>
<person name="Ishida S."/>
<person name="Ono Y."/>
<person name="Takiguchi S."/>
<person name="Watanabe S."/>
<person name="Yosida M."/>
<person name="Hotuta T."/>
<person name="Kusano J."/>
<person name="Kanehori K."/>
<person name="Takahashi-Fujii A."/>
<person name="Hara H."/>
<person name="Tanase T.-O."/>
<person name="Nomura Y."/>
<person name="Togiya S."/>
<person name="Komai F."/>
<person name="Hara R."/>
<person name="Takeuchi K."/>
<person name="Arita M."/>
<person name="Imose N."/>
<person name="Musashino K."/>
<person name="Yuuki H."/>
<person name="Oshima A."/>
<person name="Sasaki N."/>
<person name="Aotsuka S."/>
<person name="Yoshikawa Y."/>
<person name="Matsunawa H."/>
<person name="Ichihara T."/>
<person name="Shiohata N."/>
<person name="Sano S."/>
<person name="Moriya S."/>
<person name="Momiyama H."/>
<person name="Satoh N."/>
<person name="Takami S."/>
<person name="Terashima Y."/>
<person name="Suzuki O."/>
<person name="Nakagawa S."/>
<person name="Senoh A."/>
<person name="Mizoguchi H."/>
<person name="Goto Y."/>
<person name="Shimizu F."/>
<person name="Wakebe H."/>
<person name="Hishigaki H."/>
<person name="Watanabe T."/>
<person name="Sugiyama A."/>
<person name="Takemoto M."/>
<person name="Kawakami B."/>
<person name="Yamazaki M."/>
<person name="Watanabe K."/>
<person name="Kumagai A."/>
<person name="Itakura S."/>
<person name="Fukuzumi Y."/>
<person name="Fujimori Y."/>
<person name="Komiyama M."/>
<person name="Tashiro H."/>
<person name="Tanigami A."/>
<person name="Fujiwara T."/>
<person name="Ono T."/>
<person name="Yamada K."/>
<person name="Fujii Y."/>
<person name="Ozaki K."/>
<person name="Hirao M."/>
<person name="Ohmori Y."/>
<person name="Kawabata A."/>
<person name="Hikiji T."/>
<person name="Kobatake N."/>
<person name="Inagaki H."/>
<person name="Ikema Y."/>
<person name="Okamoto S."/>
<person name="Okitani R."/>
<person name="Kawakami T."/>
<person name="Noguchi S."/>
<person name="Itoh T."/>
<person name="Shigeta K."/>
<person name="Senba T."/>
<person name="Matsumura K."/>
<person name="Nakajima Y."/>
<person name="Mizuno T."/>
<person name="Morinaga M."/>
<person name="Sasaki M."/>
<person name="Togashi T."/>
<person name="Oyama M."/>
<person name="Hata H."/>
<person name="Watanabe M."/>
<person name="Komatsu T."/>
<person name="Mizushima-Sugano J."/>
<person name="Satoh T."/>
<person name="Shirai Y."/>
<person name="Takahashi Y."/>
<person name="Nakagawa K."/>
<person name="Okumura K."/>
<person name="Nagase T."/>
<person name="Nomura N."/>
<person name="Kikuchi H."/>
<person name="Masuho Y."/>
<person name="Yamashita R."/>
<person name="Nakai K."/>
<person name="Yada T."/>
<person name="Nakamura Y."/>
<person name="Ohara O."/>
<person name="Isogai T."/>
<person name="Sugano S."/>
</authorList>
<dbReference type="PubMed" id="14702039"/>
<dbReference type="DOI" id="10.1038/ng1285"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1)</scope>
<source>
<tissue>Colon</tissue>
</source>
</reference>
<reference key="5">
<citation type="journal article" date="2006" name="Nature" volume="440" first="346" last="351">
<title>The finished DNA sequence of human chromosome 12.</title>
<authorList>
<person name="Scherer S.E."/>
<person name="Muzny D.M."/>
<person name="Buhay C.J."/>
<person name="Chen R."/>
<person name="Cree A."/>
<person name="Ding Y."/>
<person name="Dugan-Rocha S."/>
<person name="Gill R."/>
<person name="Gunaratne P."/>
<person name="Harris R.A."/>
<person name="Hawes A.C."/>
<person name="Hernandez J."/>
<person name="Hodgson A.V."/>
<person name="Hume J."/>
<person name="Jackson A."/>
<person name="Khan Z.M."/>
<person name="Kovar-Smith C."/>
<person name="Lewis L.R."/>
<person name="Lozado R.J."/>
<person name="Metzker M.L."/>
<person name="Milosavljevic A."/>
<person name="Miner G.R."/>
<person name="Montgomery K.T."/>
<person name="Morgan M.B."/>
<person name="Nazareth L.V."/>
<person name="Scott G."/>
<person name="Sodergren E."/>
<person name="Song X.-Z."/>
<person name="Steffen D."/>
<person name="Lovering R.C."/>
<person name="Wheeler D.A."/>
<person name="Worley K.C."/>
<person name="Yuan Y."/>
<person name="Zhang Z."/>
<person name="Adams C.Q."/>
<person name="Ansari-Lari M.A."/>
<person name="Ayele M."/>
<person name="Brown M.J."/>
<person name="Chen G."/>
<person name="Chen Z."/>
<person name="Clerc-Blankenburg K.P."/>
<person name="Davis C."/>
<person name="Delgado O."/>
<person name="Dinh H.H."/>
<person name="Draper H."/>
<person name="Gonzalez-Garay M.L."/>
<person name="Havlak P."/>
<person name="Jackson L.R."/>
<person name="Jacob L.S."/>
<person name="Kelly S.H."/>
<person name="Li L."/>
<person name="Li Z."/>
<person name="Liu J."/>
<person name="Liu W."/>
<person name="Lu J."/>
<person name="Maheshwari M."/>
<person name="Nguyen B.-V."/>
<person name="Okwuonu G.O."/>
<person name="Pasternak S."/>
<person name="Perez L.M."/>
<person name="Plopper F.J.H."/>
<person name="Santibanez J."/>
<person name="Shen H."/>
<person name="Tabor P.E."/>
<person name="Verduzco D."/>
<person name="Waldron L."/>
<person name="Wang Q."/>
<person name="Williams G.A."/>
<person name="Zhang J."/>
<person name="Zhou J."/>
<person name="Allen C.C."/>
<person name="Amin A.G."/>
<person name="Anyalebechi V."/>
<person name="Bailey M."/>
<person name="Barbaria J.A."/>
<person name="Bimage K.E."/>
<person name="Bryant N.P."/>
<person name="Burch P.E."/>
<person name="Burkett C.E."/>
<person name="Burrell K.L."/>
<person name="Calderon E."/>
<person name="Cardenas V."/>
<person name="Carter K."/>
<person name="Casias K."/>
<person name="Cavazos I."/>
<person name="Cavazos S.R."/>
<person name="Ceasar H."/>
<person name="Chacko J."/>
<person name="Chan S.N."/>
<person name="Chavez D."/>
<person name="Christopoulos C."/>
<person name="Chu J."/>
<person name="Cockrell R."/>
<person name="Cox C.D."/>
<person name="Dang M."/>
<person name="Dathorne S.R."/>
<person name="David R."/>
<person name="Davis C.M."/>
<person name="Davy-Carroll L."/>
<person name="Deshazo D.R."/>
<person name="Donlin J.E."/>
<person name="D'Souza L."/>
<person name="Eaves K.A."/>
<person name="Egan A."/>
<person name="Emery-Cohen A.J."/>
<person name="Escotto M."/>
<person name="Flagg N."/>
<person name="Forbes L.D."/>
<person name="Gabisi A.M."/>
<person name="Garza M."/>
<person name="Hamilton C."/>
<person name="Henderson N."/>
<person name="Hernandez O."/>
<person name="Hines S."/>
<person name="Hogues M.E."/>
<person name="Huang M."/>
<person name="Idlebird D.G."/>
<person name="Johnson R."/>
<person name="Jolivet A."/>
<person name="Jones S."/>
<person name="Kagan R."/>
<person name="King L.M."/>
<person name="Leal B."/>
<person name="Lebow H."/>
<person name="Lee S."/>
<person name="LeVan J.M."/>
<person name="Lewis L.C."/>
<person name="London P."/>
<person name="Lorensuhewa L.M."/>
<person name="Loulseged H."/>
<person name="Lovett D.A."/>
<person name="Lucier A."/>
<person name="Lucier R.L."/>
<person name="Ma J."/>
<person name="Madu R.C."/>
<person name="Mapua P."/>
<person name="Martindale A.D."/>
<person name="Martinez E."/>
<person name="Massey E."/>
<person name="Mawhiney S."/>
<person name="Meador M.G."/>
<person name="Mendez S."/>
<person name="Mercado C."/>
<person name="Mercado I.C."/>
<person name="Merritt C.E."/>
<person name="Miner Z.L."/>
<person name="Minja E."/>
<person name="Mitchell T."/>
<person name="Mohabbat F."/>
<person name="Mohabbat K."/>
<person name="Montgomery B."/>
<person name="Moore N."/>
<person name="Morris S."/>
<person name="Munidasa M."/>
<person name="Ngo R.N."/>
<person name="Nguyen N.B."/>
<person name="Nickerson E."/>
<person name="Nwaokelemeh O.O."/>
<person name="Nwokenkwo S."/>
<person name="Obregon M."/>
<person name="Oguh M."/>
<person name="Oragunye N."/>
<person name="Oviedo R.J."/>
<person name="Parish B.J."/>
<person name="Parker D.N."/>
<person name="Parrish J."/>
<person name="Parks K.L."/>
<person name="Paul H.A."/>
<person name="Payton B.A."/>
<person name="Perez A."/>
<person name="Perrin W."/>
<person name="Pickens A."/>
<person name="Primus E.L."/>
<person name="Pu L.-L."/>
<person name="Puazo M."/>
<person name="Quiles M.M."/>
<person name="Quiroz J.B."/>
<person name="Rabata D."/>
<person name="Reeves K."/>
<person name="Ruiz S.J."/>
<person name="Shao H."/>
<person name="Sisson I."/>
<person name="Sonaike T."/>
<person name="Sorelle R.P."/>
<person name="Sutton A.E."/>
<person name="Svatek A.F."/>
<person name="Svetz L.A."/>
<person name="Tamerisa K.S."/>
<person name="Taylor T.R."/>
<person name="Teague B."/>
<person name="Thomas N."/>
<person name="Thorn R.D."/>
<person name="Trejos Z.Y."/>
<person name="Trevino B.K."/>
<person name="Ukegbu O.N."/>
<person name="Urban J.B."/>
<person name="Vasquez L.I."/>
<person name="Vera V.A."/>
<person name="Villasana D.M."/>
<person name="Wang L."/>
<person name="Ward-Moore S."/>
<person name="Warren J.T."/>
<person name="Wei X."/>
<person name="White F."/>
<person name="Williamson A.L."/>
<person name="Wleczyk R."/>
<person name="Wooden H.S."/>
<person name="Wooden S.H."/>
<person name="Yen J."/>
<person name="Yoon L."/>
<person name="Yoon V."/>
<person name="Zorrilla S.E."/>
<person name="Nelson D."/>
<person name="Kucherlapati R."/>
<person name="Weinstock G."/>
<person name="Gibbs R.A."/>
</authorList>
<dbReference type="PubMed" id="16541075"/>
<dbReference type="DOI" id="10.1038/nature04569"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="6">
<citation type="submission" date="2005-07" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Mural R.J."/>
<person name="Istrail S."/>
<person name="Sutton G.G."/>
<person name="Florea L."/>
<person name="Halpern A.L."/>
<person name="Mobarry C.M."/>
<person name="Lippert R."/>
<person name="Walenz B."/>
<person name="Shatkay H."/>
<person name="Dew I."/>
<person name="Miller J.R."/>
<person name="Flanigan M.J."/>
<person name="Edwards N.J."/>
<person name="Bolanos R."/>
<person name="Fasulo D."/>
<person name="Halldorsson B.V."/>
<person name="Hannenhalli S."/>
<person name="Turner R."/>
<person name="Yooseph S."/>
<person name="Lu F."/>
<person name="Nusskern D.R."/>
<person name="Shue B.C."/>
<person name="Zheng X.H."/>
<person name="Zhong F."/>
<person name="Delcher A.L."/>
<person name="Huson D.H."/>
<person name="Kravitz S.A."/>
<person name="Mouchard L."/>
<person name="Reinert K."/>
<person name="Remington K.A."/>
<person name="Clark A.G."/>
<person name="Waterman M.S."/>
<person name="Eichler E.E."/>
<person name="Adams M.D."/>
<person name="Hunkapiller M.W."/>
<person name="Myers E.W."/>
<person name="Venter J.C."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="7">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 5)</scope>
</reference>
<reference key="8">
<citation type="journal article" date="1999" name="J. Biol. Chem." volume="274" first="29749" last="29754">
<title>Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer.</title>
<authorList>
<person name="Grober J."/>
<person name="Zaghini I."/>
<person name="Fujii H."/>
<person name="Jones S.A."/>
<person name="Kliewer S.A."/>
<person name="Willson T.M."/>
<person name="Ono T."/>
<person name="Besnard P."/>
</authorList>
<dbReference type="PubMed" id="10514450"/>
<dbReference type="DOI" id="10.1074/jbc.274.42.29749"/>
</citation>
<scope>FUNCTION IN BA HOMEOSTASIS</scope>
</reference>
<reference key="9">
<citation type="journal article" date="1999" name="Science" volume="284" first="1362" last="1365">
<title>Identification of a nuclear receptor for bile acids.</title>
<authorList>
<person name="Makishima M."/>
<person name="Okamoto A.Y."/>
<person name="Repa J.J."/>
<person name="Tu H."/>
<person name="Learned R.M."/>
<person name="Luk A."/>
<person name="Hull M.V."/>
<person name="Lustig K.D."/>
<person name="Mangelsdorf D.J."/>
<person name="Shan B."/>
</authorList>
<dbReference type="PubMed" id="10334992"/>
<dbReference type="DOI" id="10.1126/science.284.5418.1362"/>
</citation>
<scope>FUNCTION IN BA HOEMOSTASIS</scope>
</reference>
<reference key="10">
<citation type="journal article" date="1999" name="Science" volume="284" first="1365" last="1368">
<title>Bile acids: natural ligands for an orphan nuclear receptor.</title>
<authorList>
<person name="Parks D.J."/>
<person name="Blanchard S.G."/>
<person name="Bledsoe R.K."/>
<person name="Chandra G."/>
<person name="Consler T.G."/>
<person name="Kliewer S.A."/>
<person name="Stimmel J.B."/>
<person name="Willson T.M."/>
<person name="Zavacki A.M."/>
<person name="Moore D.D."/>
<person name="Lehmann J.M."/>
</authorList>
<dbReference type="PubMed" id="10334993"/>
<dbReference type="DOI" id="10.1126/science.284.5418.1365"/>
</citation>
<scope>FUNCTION IN BA HOEMOSTASIS</scope>
</reference>
<reference key="11">
<citation type="journal article" date="2001" name="Mol. Endocrinol." volume="15" first="1720" last="1728">
<title>Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids.</title>
<authorList>
<person name="Kast H.R."/>
<person name="Nguyen C.M."/>
<person name="Sinal C.J."/>
<person name="Jones S.A."/>
<person name="Laffitte B.A."/>
<person name="Reue K."/>
<person name="Gonzalez F.J."/>
<person name="Willson T.M."/>
<person name="Edwards P.A."/>
</authorList>
<dbReference type="PubMed" id="11579204"/>
<dbReference type="DOI" id="10.1210/mend.15.10.0712"/>
</citation>
<scope>FUNCTION IN LIPID HOMEOSTASIS</scope>
</reference>
<reference key="12">
<citation type="journal article" date="2002" name="J. Clin. Invest." volume="109" first="961" last="971">
<title>Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element.</title>
<authorList>
<person name="Claudel T."/>
<person name="Sturm E."/>
<person name="Duez H."/>
<person name="Torra I.P."/>
<person name="Sirvent A."/>
<person name="Kosykh V."/>
<person name="Fruchart J.C."/>
<person name="Dallongeville J."/>
<person name="Hum D.W."/>
<person name="Kuipers F."/>
<person name="Staels B."/>
</authorList>
<dbReference type="PubMed" id="11927623"/>
<dbReference type="DOI" id="10.1172/jci14505"/>
</citation>
<scope>FUNCTION IN LIPID HOMEOSTASIS</scope>
</reference>
<reference key="13">
<citation type="journal article" date="2003" name="Genes Dev." volume="17" first="1581" last="1591">
<title>Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis.</title>
<authorList>
<person name="Holt J.A."/>
<person name="Luo G."/>
<person name="Billin A.N."/>
<person name="Bisi J."/>
<person name="McNeill Y.Y."/>
<person name="Kozarsky K.F."/>
<person name="Donahee M."/>
<person name="Wang D.Y."/>
<person name="Mansfield T.A."/>
<person name="Kliewer S.A."/>
<person name="Goodwin B."/>
<person name="Jones S.A."/>
</authorList>
<dbReference type="PubMed" id="12815072"/>
<dbReference type="DOI" id="10.1101/gad.1083503"/>
</citation>
<scope>FUNCTION IN BA HOMEOSTASIS</scope>
</reference>
<reference key="14">
<citation type="journal article" date="2003" name="Gastroenterology" volume="124" first="1926" last="1940">
<title>FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity.</title>
<authorList>
<person name="Barbier O."/>
<person name="Torra I.P."/>
<person name="Sirvent A."/>
<person name="Claudel T."/>
<person name="Blanquart C."/>
<person name="Duran-Sandoval D."/>
<person name="Kuipers F."/>
<person name="Kosykh V."/>
<person name="Fruchart J.C."/>
<person name="Staels B."/>
</authorList>
<dbReference type="PubMed" id="12806625"/>
<dbReference type="DOI" id="10.1016/s0016-5085(03)00388-3"/>
</citation>
<scope>FUNCTION IN BA HOMEOSTASIS</scope>
</reference>
<reference key="15">
<citation type="journal article" date="2003" name="Gastroenterology" volume="125" first="544" last="555">
<title>Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression.</title>
<authorList>
<person name="Claudel T."/>
<person name="Inoue Y."/>
<person name="Barbier O."/>
<person name="Duran-Sandoval D."/>
<person name="Kosykh V."/>
<person name="Fruchart J."/>
<person name="Fruchart J.C."/>
<person name="Gonzalez F.J."/>
<person name="Staels B."/>
</authorList>
<dbReference type="PubMed" id="12891557"/>
<dbReference type="DOI" id="10.1016/s0016-5085(03)00896-5"/>
</citation>
<scope>FUNCTION IN LIPID HOMEOSTASIS</scope>
</reference>
<reference key="16">
<citation type="journal article" date="2003" name="J. Biol. Chem." volume="278" first="20420" last="20428">
<title>Syndecan-1 expression is regulated in an isoform-specific manner by the farnesoid-X receptor.</title>
<authorList>
<person name="Anisfeld A.M."/>
<person name="Kast-Woelbern H.R."/>
<person name="Meyer M.E."/>
<person name="Jones S.A."/>
<person name="Zhang Y."/>
<person name="Williams K.J."/>
<person name="Willson T."/>
<person name="Edwards P.A."/>
</authorList>
<dbReference type="PubMed" id="12660231"/>
<dbReference type="DOI" id="10.1074/jbc.m302505200"/>
</citation>
<scope>FUNCTION IN LIPID HOMEOSTASIS</scope>
</reference>
<reference key="17">
<citation type="journal article" date="2003" name="J. Biol. Chem." volume="278" first="27703" last="27711">
<title>Farnesoid X receptor regulates bile acid-amino acid conjugation.</title>
<authorList>
<person name="Pircher P.C."/>
<person name="Kitto J.L."/>
<person name="Petrowski M.L."/>
<person name="Tangirala R.K."/>
<person name="Bischoff E.D."/>
<person name="Schulman I.G."/>
<person name="Westin S.K."/>
</authorList>
<dbReference type="PubMed" id="12754200"/>
<dbReference type="DOI" id="10.1074/jbc.m302128200"/>
</citation>
<scope>FUNCTION IN BA HOMEOSTASIS</scope>
</reference>
<reference key="18">
<citation type="journal article" date="2003" name="Mol. Endocrinol." volume="17" first="259" last="272">
<title>Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.</title>
<authorList>
<person name="Pineda Torra I."/>
<person name="Claudel T."/>
<person name="Duval C."/>
<person name="Kosykh V."/>
<person name="Fruchart J.C."/>
<person name="Staels B."/>
</authorList>
<dbReference type="PubMed" id="12554753"/>
<dbReference type="DOI" id="10.1210/me.2002-0120"/>
</citation>
<scope>FUNCTION IN LIPID HOMEOSTASIS</scope>
</reference>
<reference key="19">
<citation type="journal article" date="2004" name="Biochem. J." volume="382" first="913" last="921">
<title>The nuclear bile acid receptor FXR is activated by PGC-1alpha in a ligand-dependent manner.</title>
<authorList>
<person name="Kanaya E."/>
<person name="Shiraki T."/>
<person name="Jingami H."/>
</authorList>
<dbReference type="PubMed" id="15202934"/>
<dbReference type="DOI" id="10.1042/bj20040432"/>
</citation>
<scope>INTERACTION WITH PPARGC1A</scope>
</reference>
<reference key="20">
<citation type="journal article" date="2004" name="J. Biol. Chem." volume="279" first="8856" last="8861">
<title>The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion.</title>
<authorList>
<person name="Lew J.L."/>
<person name="Zhao A."/>
<person name="Yu J."/>
<person name="Huang L."/>
<person name="De Pedro N."/>
<person name="Pelaez F."/>
<person name="Wright S.D."/>
<person name="Cui J."/>
</authorList>
<dbReference type="PubMed" id="14684751"/>
<dbReference type="DOI" id="10.1074/jbc.m306422200"/>
</citation>
<scope>INTERACTION WITH NCOA1</scope>
<scope>LIGAND-BINDING</scope>
</reference>
<reference key="21">
<citation type="journal article" date="2004" name="Hepatology" volume="40" first="149" last="156">
<title>Bile acid-induced negative feedback regulation of the human ileal bile acid transporter.</title>
<authorList>
<person name="Neimark E."/>
<person name="Chen F."/>
<person name="Li X."/>
<person name="Shneider B.L."/>
</authorList>
<dbReference type="PubMed" id="15239098"/>
<dbReference type="DOI" id="10.1002/hep.20295"/>
</citation>
<scope>FUNCTION IN BA HOEMOSTASIS</scope>
</reference>
<reference key="22">
<citation type="journal article" date="2004" name="J. Biol. Chem." volume="279" first="36184" last="36191">
<title>Identification of DRIP205 as a coactivator for the Farnesoid X receptor.</title>
<authorList>
<person name="Pineda Torra I."/>
<person name="Freedman L.P."/>
<person name="Garabedian M.J."/>
</authorList>
<dbReference type="PubMed" id="15187081"/>
<dbReference type="DOI" id="10.1074/jbc.m405126200"/>
</citation>
<scope>INTERACTION WITH MED1</scope>
</reference>
<reference key="23">
<citation type="journal article" date="2004" name="J. Biol. Chem." volume="279" first="45685" last="45692">
<title>Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4.</title>
<authorList>
<person name="Hirokane H."/>
<person name="Nakahara M."/>
<person name="Tachibana S."/>
<person name="Shimizu M."/>
<person name="Sato R."/>
</authorList>
<dbReference type="PubMed" id="15337761"/>
<dbReference type="DOI" id="10.1074/jbc.m404255200"/>
</citation>
<scope>FUNCTION IN LIPID HOMEOSTASIS</scope>
</reference>
<reference key="24">
<citation type="journal article" date="2004" name="J. Biol. Chem." volume="279" first="54348" last="54357">
<title>Ligand-dependent activation of the farnesoid X-receptor directs arginine methylation of histone H3 by CARM1.</title>
<authorList>
<person name="Ananthanarayanan M."/>
<person name="Li S."/>
<person name="Balasubramaniyan N."/>
<person name="Suchy F.J."/>
<person name="Walsh M.J."/>
</authorList>
<dbReference type="PubMed" id="15471871"/>
<dbReference type="DOI" id="10.1074/jbc.m410021200"/>
</citation>
<scope>FUNCTION IN BA HOMEOSTASIS</scope>
<scope>INTERACTION WITH CARM1</scope>
</reference>
<reference key="25">
<citation type="journal article" date="2005" name="Mol. Pharmacol." volume="68" first="551" last="558">
<title>The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes.</title>
<authorList>
<person name="Rizzo G."/>
<person name="Renga B."/>
<person name="Antonelli E."/>
<person name="Passeri D."/>
<person name="Pellicciari R."/>
<person name="Fiorucci S."/>
</authorList>
<dbReference type="PubMed" id="15911693"/>
<dbReference type="DOI" id="10.1124/mol.105.012104"/>
</citation>
<scope>INTERACTION WITH PRMT1</scope>
</reference>
<reference key="26">
<citation type="journal article" date="2006" name="Am. J. Physiol." volume="290" first="G476" last="G485">
<title>The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes.</title>
<authorList>
<person name="Landrier J.-F."/>
<person name="Eloranta J.J."/>
<person name="Vavricka S.R."/>
<person name="Kullak-Ublick G.A."/>
</authorList>
<dbReference type="PubMed" id="16269519"/>
<dbReference type="DOI" id="10.1152/ajpgi.00430.2005"/>
</citation>
<scope>FUNCTION IN BA HOEMOSTASIS</scope>
</reference>
<reference key="27">
<citation type="journal article" date="2006" name="Drug Metab. Pharmacokinet." volume="21" first="315" last="323">
<title>Chenodeoxycholic acid-mediated activation of the farnesoid X receptor negatively regulates hydroxysteroid sulfotransferase.</title>
<authorList>
<person name="Miyata M."/>
<person name="Matsuda Y."/>
<person name="Tsuchiya H."/>
<person name="Kitada H."/>
<person name="Akase T."/>
<person name="Shimada M."/>
<person name="Nagata K."/>
<person name="Gonzalez F.J."/>
<person name="Yamazoe Y."/>
</authorList>
<dbReference type="PubMed" id="16946559"/>
<dbReference type="DOI" id="10.2133/dmpk.21.315"/>
</citation>
<scope>FUNCTION IN BA HOEMOSTASIS</scope>
</reference>
<reference key="28">
<citation type="journal article" date="2007" name="Gastroenterology" volume="133" first="507" last="516">
<title>Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy.</title>
<authorList>
<person name="Van Mil S.W."/>
<person name="Milona A."/>
<person name="Dixon P.H."/>
<person name="Mullenbach R."/>
<person name="Geenes V.L."/>
<person name="Chambers J."/>
<person name="Shevchuk V."/>
<person name="Moore G.E."/>
<person name="Lammert F."/>
<person name="Glantz A.G."/>
<person name="Mattsson L.A."/>
<person name="Whittaker J."/>
<person name="Parker M.G."/>
<person name="White R."/>
<person name="Williamson C."/>
</authorList>
<dbReference type="PubMed" id="17681172"/>
<dbReference type="DOI" id="10.1053/j.gastro.2007.05.015"/>
</citation>
<scope>POSSIBLE INVOLVEMENT IN INTRAHEPATIC CHOLESTASIS OF PREGNANCY</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2007" name="Proc. Natl. Acad. Sci. U.S.A." volume="104" first="15665" last="15670">
<title>Involvement of corepressor complex subunit GPS2 in transcriptional pathways governing human bile acid biosynthesis.</title>
<authorList>
<person name="Sanyal S."/>
<person name="Baavner A."/>
<person name="Haroniti A."/>
<person name="Nilsson L.M."/>
<person name="Lundaasen T."/>
<person name="Rehnmark S."/>
<person name="Witt M.R."/>
<person name="Einarsson C."/>
<person name="Talianidis I."/>
<person name="Gustafsson J.A."/>
<person name="Treuter E."/>
</authorList>
<dbReference type="PubMed" id="17895379"/>
<dbReference type="DOI" id="10.1073/pnas.0706736104"/>
</citation>
<scope>FUNCTION IN BA HEMOSTASIS</scope>
<scope>INTERACTION WITH GPS2</scope>
</reference>
<reference key="30">
<citation type="journal article" date="2008" name="Hepatology" volume="48" first="1896" last="1905">
<title>The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor.</title>
<authorList>
<person name="Frankenberg T."/>
<person name="Miloh T."/>
<person name="Chen F.Y."/>
<person name="Ananthanarayanan M."/>
<person name="Sun A.Q."/>
<person name="Balasubramaniyan N."/>
<person name="Arias I."/>
<person name="Setchell K.D."/>
<person name="Suchy F.J."/>
<person name="Shneider B.L."/>
</authorList>
<dbReference type="PubMed" id="18668687"/>
<dbReference type="DOI" id="10.1002/hep.22431"/>
</citation>
<scope>PHOSPHORYLATION AT THR-456</scope>
<scope>MUTAGENESIS OF THR-456</scope>
</reference>
<reference key="31">
<citation type="journal article" date="2008" name="J. Hepatol." volume="48" first="116" last="124">
<title>Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans.</title>
<authorList>
<person name="Kovacs P."/>
<person name="Kress R."/>
<person name="Rocha J."/>
<person name="Kurtz U."/>
<person name="Miquel J.F."/>
<person name="Nervi F."/>
<person name="Mendez-Sanchez N."/>
<person name="Uribe M."/>
<person name="Bock H.H."/>
<person name="Schirin-Sokhan R."/>
<person name="Stumvoll M."/>
<person name="Moessner J."/>
<person name="Lammert F."/>
<person name="Wittenburg H."/>
</authorList>
<dbReference type="PubMed" id="17931734"/>
<dbReference type="DOI" id="10.1016/j.jhep.2007.07.027"/>
</citation>
<scope>POSSIBLE INVOLVEMENT IN CHOLESTEROL CHOLELITHIASIS</scope>
</reference>
<reference key="32">
<citation type="journal article" date="2008" name="Mol. Endocrinol." volume="22" first="2433" last="2447">
<title>Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity.</title>
<authorList>
<person name="Gineste R."/>
<person name="Sirvent A."/>
<person name="Paumelle R."/>
<person name="Helleboid S."/>
<person name="Aquilina A."/>
<person name="Darteil R."/>
<person name="Hum D.W."/>
<person name="Fruchart J.C."/>
<person name="Staels B."/>
</authorList>
<dbReference type="PubMed" id="18755856"/>
<dbReference type="DOI" id="10.1210/me.2008-0092"/>
</citation>
<scope>PHOSPHORYLATION AT SER-145 AND SER-164</scope>
<scope>INTERACTION WITH PPARGC1A</scope>
<scope>MUTAGENESIS OF SER-145 AND SER-164</scope>
</reference>
<reference key="33">
<citation type="journal article" date="2009" name="Biochem. Biophys. Res. Commun." volume="390" first="738" last="742">
<title>Ku proteins function as corepressors to regulate farnesoid X receptor-mediated gene expression.</title>
<authorList>
<person name="Ohno M."/>
<person name="Kunimoto M."/>
<person name="Nishizuka M."/>
<person name="Osada S."/>
<person name="Imagawa M."/>
</authorList>
<dbReference type="PubMed" id="19833092"/>
<dbReference type="DOI" id="10.1016/j.bbrc.2009.10.040"/>
</citation>
<scope>INTERACTION WITH XRCC5 AND XRCC6</scope>
</reference>
<reference key="34">
<citation type="journal article" date="2009" name="Biochim. Biophys. Acta" volume="1792" first="564" last="573">
<title>Reciprocal regulation of the bile acid-activated receptor FXR and the interferon-gamma-STAT-1 pathway in macrophages.</title>
<authorList>
<person name="Renga B."/>
<person name="Migliorati M."/>
<person name="Mencarelli A."/>
<person name="Fiorucci S."/>
</authorList>
<dbReference type="PubMed" id="19393742"/>
<dbReference type="DOI" id="10.1016/j.bbadis.2009.04.004"/>
</citation>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="35">
<citation type="journal article" date="2009" name="Cell Metab." volume="10" first="392" last="404">
<title>FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states.</title>
<authorList>
<person name="Kemper J.K."/>
<person name="Xiao Z."/>
<person name="Ponugoti B."/>
<person name="Miao J."/>
<person name="Fang S."/>
<person name="Kanamaluru D."/>
<person name="Tsang S."/>
<person name="Wu S.Y."/>
<person name="Chiang C.M."/>
<person name="Veenstra T.D."/>
</authorList>
<dbReference type="PubMed" id="19883617"/>
<dbReference type="DOI" id="10.1016/j.cmet.2009.09.009"/>
</citation>
<scope>ACETYLATION AT LYS-167 AND LYS-227 BY EP300</scope>
</reference>
<reference key="36">
<citation type="journal article" date="2009" name="J. Immunol." volume="183" first="6251" last="6261">
<title>The bile acid receptor FXR is a modulator of intestinal innate immunity.</title>
<authorList>
<person name="Vavassori P."/>
<person name="Mencarelli A."/>
<person name="Renga B."/>
<person name="Distrutti E."/>
<person name="Fiorucci S."/>
</authorList>
<dbReference type="PubMed" id="19864602"/>
<dbReference type="DOI" id="10.4049/jimmunol.0803978"/>
</citation>
<scope>FUNCTION IN INTESTINAL INNATE IMMUNITY</scope>
<scope>TISSUE SPECIFICITY</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>SUMOYLATION</scope>
</reference>
<reference key="37">
<citation type="journal article" date="2009" name="Hepatology" volume="49" first="297" last="305">
<title>Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression.</title>
<authorList>
<person name="Song K.H."/>
<person name="Li T."/>
<person name="Owsley E."/>
<person name="Strom S."/>
<person name="Chiang J.Y."/>
</authorList>
<dbReference type="PubMed" id="19085950"/>
<dbReference type="DOI" id="10.1002/hep.22627"/>
</citation>
<scope>FUNCTION IN BA HOMEOSTASIS</scope>
</reference>
<reference key="38">
<citation type="journal article" date="2009" name="Mol. Cell. Biol." volume="29" first="6170" last="6181">
<title>Functional specificities of Brm and Brg-1 Swi/Snf ATPases in the feedback regulation of hepatic bile acid biosynthesis.</title>
<authorList>
<person name="Miao J."/>
<person name="Fang S."/>
<person name="Lee J."/>
<person name="Comstock C."/>
<person name="Knudsen K.E."/>
<person name="Kemper J.K."/>
</authorList>
<dbReference type="PubMed" id="19805516"/>
<dbReference type="DOI" id="10.1128/mcb.00825-09"/>
</citation>
<scope>INTERACTION WITH SMARCA4</scope>
</reference>
<reference key="39">
<citation type="journal article" date="2009" name="Mol. Endocrinol." volume="23" first="1556" last="1562">
<title>ASCOM controls farnesoid X receptor transactivation through its associated histone H3 lysine 4 methyltransferase activity.</title>
<authorList>
<person name="Kim D.H."/>
<person name="Lee J."/>
<person name="Lee B."/>
<person name="Lee J.W."/>
</authorList>
<dbReference type="PubMed" id="19556342"/>
<dbReference type="DOI" id="10.1210/me.2009-0099"/>
</citation>
<scope>INTERACTION WITH PAGR1 AND NCOA6</scope>
</reference>
<reference key="40">
<citation type="journal article" date="2010" name="FEBS Lett." volume="584" first="2845" last="2851">
<title>The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity.</title>
<authorList>
<person name="Popescu I.R."/>
<person name="Helleboid-Chapman A."/>
<person name="Lucas A."/>
<person name="Vandewalle B."/>
<person name="Dumont J."/>
<person name="Bouchaert E."/>
<person name="Derudas B."/>
<person name="Kerr-Conte J."/>
<person name="Caron S."/>
<person name="Pattou F."/>
<person name="Staels B."/>
</authorList>
<dbReference type="PubMed" id="20447400"/>
<dbReference type="DOI" id="10.1016/j.febslet.2010.04.068"/>
</citation>
<scope>FUNCTION IN GLUCOSE HOMEOSTASIS</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="41">
<citation type="journal article" date="2010" name="Nucl. Recept. Signal." volume="8" first="E005" last="E005">
<title>Deciphering the nuclear bile acid receptor FXR paradigm.</title>
<authorList>
<person name="Modica S."/>
<person name="Gadaleta R.M."/>
<person name="Moschetta A."/>
</authorList>
<dbReference type="PubMed" id="21383957"/>
<dbReference type="DOI" id="10.1621/nrs.08005"/>
</citation>
<scope>REVIEW</scope>
</reference>
<reference key="42">
<citation type="journal article" date="2011" name="Gut" volume="60" first="463" last="472">
<title>Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease.</title>
<authorList>
<person name="Gadaleta R.M."/>
<person name="van Erpecum K.J."/>
<person name="Oldenburg B."/>
<person name="Willemsen E.C."/>
<person name="Renooij W."/>
<person name="Murzilli S."/>
<person name="Klomp L.W."/>
<person name="Siersema P.D."/>
<person name="Schipper M.E."/>
<person name="Danese S."/>
<person name="Penna G."/>
<person name="Laverny G."/>
<person name="Adorini L."/>
<person name="Moschetta A."/>
<person name="van Mil S.W."/>
</authorList>
<dbReference type="PubMed" id="21242261"/>
<dbReference type="DOI" id="10.1136/gut.2010.212159"/>
</citation>
<scope>FUNCTION IN INTESTINAL INFLAMMATION</scope>
</reference>
<reference key="43">
<citation type="journal article" date="2011" name="J. Clin. Invest." volume="121" first="3724" last="3734">
<title>Farnesoid X receptor represses hepatic human APOA gene expression.</title>
<authorList>
<person name="Chennamsetty I."/>
<person name="Claudel T."/>
<person name="Kostner K.M."/>
<person name="Baghdasaryan A."/>
<person name="Kratky D."/>
<person name="Levak-Frank S."/>
<person name="Frank S."/>
<person name="Gonzalez F.J."/>
<person name="Trauner M."/>
<person name="Kostner G.M."/>
</authorList>
<dbReference type="PubMed" id="21804189"/>
<dbReference type="DOI" id="10.1172/jci45277"/>
</citation>
<scope>FUNCTION IN LIPID HOMEOSTASIS</scope>
</reference>
<reference key="44">
<citation type="journal article" date="2012" name="Biochim. Biophys. Acta" volume="1821" first="1443" last="1452">
<title>Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms.</title>
<authorList>
<person name="Hollman D.A."/>
<person name="Milona A."/>
<person name="van Erpecum K.J."/>
<person name="van Mil S.W."/>
</authorList>
<dbReference type="PubMed" id="22820415"/>
<dbReference type="DOI" id="10.1016/j.bbalip.2012.07.004"/>
</citation>
<scope>REVIEW</scope>
</reference>
<reference key="45">
<citation type="journal article" date="2012" name="Am. J. Physiol." volume="302" first="G937" last="G947">
<title>Direct methylation of FXR by Set7/9, a lysine methyltransferase, regulates the expression of FXR target genes.</title>
<authorList>
<person name="Balasubramaniyan N."/>
<person name="Ananthanarayanan M."/>
<person name="Suchy F.J."/>
</authorList>
<dbReference type="PubMed" id="22345554"/>
<dbReference type="DOI" id="10.1152/ajpgi.00441.2011"/>
</citation>
<scope>METHYLATION AT LYS-220 BY SETD7</scope>
</reference>
<reference key="46">
<citation type="journal article" date="2012" name="Cochrane Database Syst. Rev." volume="12" first="CD000551" last="CD000551">
<title>Ursodeoxycholic acid for primary biliary cirrhosis.</title>
<authorList>
<person name="Rudic J.S."/>
<person name="Poropat G."/>
<person name="Krstic M.N."/>
<person name="Bjelakovic G."/>
<person name="Gluud C."/>
</authorList>
<dbReference type="PubMed" id="23235576"/>
<dbReference type="DOI" id="10.1002/14651858.cd000551.pub3"/>
</citation>
<scope>POSSIBLE INVOLVEMENT IN PRIMARY BILIARY CIRRHOSIS</scope>
</reference>
<reference key="47">
<citation type="journal article" date="2013" name="Biochem. Pharmacol." volume="86" first="926" last="939">
<title>Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.</title>
<authorList>
<person name="Vaquero J."/>
<person name="Monte M.J."/>
<person name="Dominguez M."/>
<person name="Muntane J."/>
<person name="Marin J.J."/>
</authorList>
<dbReference type="PubMed" id="23928191"/>
<dbReference type="DOI" id="10.1016/j.bcp.2013.07.022"/>
</citation>
<scope>TISSUE SPECIFICITY</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>FUNCTION</scope>
</reference>
<reference key="48">
<citation type="journal article" date="2013" name="J. Biol. Chem." volume="288" first="13850" last="13862">
<title>SUMOylation of the farnesoid X receptor (FXR) regulates the expression of FXR target genes.</title>
<authorList>
<person name="Balasubramaniyan N."/>
<person name="Luo Y."/>
<person name="Sun A.Q."/>
<person name="Suchy F.J."/>
</authorList>
<dbReference type="PubMed" id="23546875"/>
<dbReference type="DOI" id="10.1074/jbc.m112.443937"/>
</citation>
<scope>SUMOYLATION AT LYS-132 AND LYS-289</scope>
<scope>MUTAGENESIS OF LYS-132; LYS-289 AND GLU-291</scope>
</reference>
<reference key="49">
<citation type="journal article" date="2013" name="Mol. Pharmacol." volume="83" first="1078" last="1086">
<title>Identification of functionally relevant lysine residues that modulate human farnesoid X receptor activation.</title>
<authorList>
<person name="Sun A.Q."/>
<person name="Luo Y."/>
<person name="Backos D.S."/>
<person name="Xu S."/>
<person name="Balasubramaniyan N."/>
<person name="Reigan P."/>
<person name="Suchy F.J."/>
</authorList>
<dbReference type="PubMed" id="23462506"/>
<dbReference type="DOI" id="10.1124/mol.113.084772"/>
</citation>
<scope>MUTAGENESIS OF LYS-132; LYS-167; LYS-220; LYS-227; LYS-353 AND LYS-474</scope>
<scope>INTERACTION WITH RXRA AND SETD7</scope>
</reference>
<reference key="50">
<citation type="journal article" date="2016" name="Nat. Commun." volume="7" first="10713" last="10713">
<title>Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis.</title>
<authorList>
<person name="Gomez-Ospina N."/>
<person name="Potter C.J."/>
<person name="Xiao R."/>
<person name="Manickam K."/>
<person name="Kim M.S."/>
<person name="Kim K.H."/>
<person name="Shneider B.L."/>
<person name="Picarsic J.L."/>
<person name="Jacobson T.A."/>
<person name="Zhang J."/>
<person name="He W."/>
<person name="Liu P."/>
<person name="Knisely A.S."/>
<person name="Finegold M.J."/>
<person name="Muzny D.M."/>
<person name="Boerwinkle E."/>
<person name="Lupski J.R."/>
<person name="Plon S.E."/>
<person name="Gibbs R.A."/>
<person name="Eng C.M."/>
<person name="Yang Y."/>
<person name="Washington G.C."/>
<person name="Porteus M.H."/>
<person name="Berquist W.E."/>
<person name="Kambham N."/>
<person name="Singh R.J."/>
<person name="Xia F."/>
<person name="Enns G.M."/>
<person name="Moore D.D."/>
</authorList>
<dbReference type="PubMed" id="26888176"/>
<dbReference type="DOI" id="10.1038/ncomms10713"/>
</citation>
<scope>INVOLVEMENT IN PFIC5</scope>
<scope>VARIANT PFIC5 LYS-149 INS</scope>
<scope>CHARACTERIZATION OF VARIANT PFIC5 LYS-149 INS (ISOFORM 4)</scope>
<scope>FUNCTION (ISOFORM 4)</scope>
</reference>
<reference key="51">
<citation type="journal article" date="2003" name="Mol. Cell" volume="11" first="1079" last="1092">
<title>A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR.</title>
<authorList>
<person name="Downes M."/>
<person name="Verdecia M.A."/>
<person name="Roecker A.J."/>
<person name="Hughes R."/>
<person name="Hogenesch J.B."/>
<person name="Kast-Woelbern H.R."/>
<person name="Bowman M.E."/>
<person name="Ferrer J.L."/>
<person name="Anisfeld A.M."/>
<person name="Edwards P.A."/>
<person name="Rosenfeld J.M."/>
<person name="Alvarez J.G."/>
<person name="Noel J.P."/>
<person name="Nicolaou K.C."/>
<person name="Evans R.M."/>
</authorList>
<dbReference type="PubMed" id="12718892"/>
<dbReference type="DOI" id="10.1016/s1097-2765(03)00104-7"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 258-476 IN COMPLEX WITH SYNTHETIC AGONIST FEXARAMINE</scope>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH NCOA1</scope>
</reference>
<reference key="52">
<citation type="journal article" date="2003" name="Mol. Cell" volume="11" first="1093" last="1100">
<title>Structural basis for bile acid binding and activation of the nuclear receptor FXR.</title>
<authorList>
<person name="Mi L.Z."/>
<person name="Devarakonda S."/>
<person name="Harp J.M."/>
<person name="Han Q."/>
<person name="Pellicciari R."/>
<person name="Willson T.M."/>
<person name="Khorasanizadeh S."/>
<person name="Rastinejad F."/>
</authorList>
<dbReference type="PubMed" id="12718893"/>
<dbReference type="DOI" id="10.1016/s1097-2765(03)00112-6"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 241-469 IN COMPLEXES WITH CHENODEOXYCHOLIC ACID ANALOGS AND NCOA2 COACTIVATOR PEPTIDE</scope>
</reference>
<reference key="53">
<citation type="journal article" date="2008" name="Bioorg. Med. Chem. Lett." volume="18" first="4339" last="4343">
<title>Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.</title>
<authorList>
<person name="Akwabi-Ameyaw A."/>
<person name="Bass J.Y."/>
<person name="Caldwell R.D."/>
<person name="Caravella J.A."/>
<person name="Chen L."/>
<person name="Creech K.L."/>
<person name="Deaton D.N."/>
<person name="Jones S.A."/>
<person name="Kaldor I."/>
<person name="Liu Y."/>
<person name="Madauss K.P."/>
<person name="Marr H.B."/>
<person name="McFadyen R.B."/>
<person name="Miller A.B."/>
<person name="Iii F.N."/>
<person name="Parks D.J."/>
<person name="Spearing P.K."/>
<person name="Todd D."/>
<person name="Williams S.P."/>
<person name="Wisely G.B."/>
</authorList>
<dbReference type="PubMed" id="18621523"/>
<dbReference type="DOI" id="10.1016/j.bmcl.2008.06.073"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 252-486 IN COMPLEX WITH SYNTHETIC AGONIST</scope>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH NCOA1</scope>
</reference>
<reference key="54">
<citation type="journal article" date="2008" name="Proc. Natl. Acad. Sci. U.S.A." volume="105" first="5337" last="5342">
<title>Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation.</title>
<authorList>
<person name="Soisson S.M."/>
<person name="Parthasarathy G."/>
<person name="Adams A.D."/>
<person name="Sahoo S."/>
<person name="Sitlani A."/>
<person name="Sparrow C."/>
<person name="Cui J."/>
<person name="Becker J.W."/>
</authorList>
<dbReference type="PubMed" id="18391212"/>
<dbReference type="DOI" id="10.1073/pnas.0710981105"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 249-486 IN COMPLEX WITH STEROID ANALOG MFA-1 AND NCOA1 PEPTIDE</scope>
<scope>INTERACTION WITH NCOA1</scope>
<scope>DOMAIN</scope>
</reference>
<reference key="55">
<citation type="journal article" date="2009" name="Bioorg. Med. Chem. Lett." volume="19" first="2969" last="2973">
<title>Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064.</title>
<authorList>
<person name="Bass J.Y."/>
<person name="Caldwell R.D."/>
<person name="Caravella J.A."/>
<person name="Chen L."/>
<person name="Creech K.L."/>
<person name="Deaton D.N."/>
<person name="Madauss K.P."/>
<person name="Marr H.B."/>
<person name="McFadyen R.B."/>
<person name="Miller A.B."/>
<person name="Parks D.J."/>
<person name="Todd D."/>
<person name="Williams S.P."/>
<person name="Wisely G.B."/>
</authorList>
<dbReference type="PubMed" id="19410460"/>
<dbReference type="DOI" id="10.1016/j.bmcl.2009.04.047"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 260-486 IN COMPLEX WITH SYNTHETIC AGONIST</scope>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH NCOA1</scope>
</reference>
<reference key="56">
<citation type="journal article" date="2009" name="Bioorg. Med. Chem. Lett." volume="19" first="4733" last="4739">
<title>FXR agonist activity of conformationally constrained analogs of GW 4064.</title>
<authorList>
<person name="Akwabi-Ameyaw A."/>
<person name="Bass J.Y."/>
<person name="Caldwell R.D."/>
<person name="Caravella J.A."/>
<person name="Chen L."/>
<person name="Creech K.L."/>
<person name="Deaton D.N."/>
<person name="Madauss K.P."/>
<person name="Marr H.B."/>
<person name="McFadyen R.B."/>
<person name="Miller A.B."/>
<person name="Navas F. III"/>
<person name="Parks D.J."/>
<person name="Spearing P.K."/>
<person name="Todd D."/>
<person name="Williams S.P."/>
<person name="Bruce Wisely G."/>
</authorList>
<dbReference type="PubMed" id="19586769"/>
<dbReference type="DOI" id="10.1016/j.bmcl.2009.06.062"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 257-486 IN COMPLEX WITH SYNTHETIC AGONIST</scope>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH NCOA1</scope>
</reference>
<reference key="57">
<citation type="journal article" date="2009" name="J. Med. Chem." volume="52" first="904" last="907">
<title>Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR).</title>
<authorList>
<person name="Flatt B."/>
<person name="Martin R."/>
<person name="Wang T.L."/>
<person name="Mahaney P."/>
<person name="Murphy B."/>
<person name="Gu X.H."/>
<person name="Foster P."/>
<person name="Li J."/>
<person name="Pircher P."/>
<person name="Petrowski M."/>
<person name="Schulman I."/>
<person name="Westin S."/>
<person name="Wrobel J."/>
<person name="Yan G."/>
<person name="Bischoff E."/>
<person name="Daige C."/>
<person name="Mohan R."/>
</authorList>
<dbReference type="PubMed" id="19159286"/>
<dbReference type="DOI" id="10.1021/jm8014124"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 258-486 IN COMPLEX WITH SYNTHETIC AGONIST</scope>
</reference>
<reference key="58">
<citation type="journal article" date="2010" name="J. Med. Chem." volume="53" first="1774" last="1787">
<title>Improvement of physiochemical properties of the tetrahydroazepinoindole series of farnesoid X receptor (FXR) agonists: beneficial modulation of lipids in primates.</title>
<authorList>
<person name="Lundquist J.T."/>
<person name="Harnish D.C."/>
<person name="Kim C.Y."/>
<person name="Mehlmann J.F."/>
<person name="Unwalla R.J."/>
<person name="Phipps K.M."/>
<person name="Crawley M.L."/>
<person name="Commons T."/>
<person name="Green D.M."/>
<person name="Xu W."/>
<person name="Hum W.T."/>
<person name="Eta J.E."/>
<person name="Feingold I."/>
<person name="Patel V."/>
<person name="Evans M.J."/>
<person name="Lai K."/>
<person name="Borges-Marcucci L."/>
<person name="Mahaney P.E."/>
<person name="Wrobel J.E."/>
</authorList>
<dbReference type="PubMed" id="20095622"/>
<dbReference type="DOI" id="10.1021/jm901650u"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 248-476 IN COMPLEX WITH SYNTHETIC AGONIST</scope>
</reference>
<reference key="59" evidence="6">
<citation type="journal article" date="2018" name="J. Biol. Chem." volume="293" first="18180" last="18191">
<title>Ligand binding and heterodimerization with retinoid X receptor alpha (RXRalpha) induce farnesoid X receptor (FXR) conformational changes affecting coactivator binding.</title>
<authorList>
<person name="Wang N."/>
<person name="Zou Q."/>
<person name="Xu J."/>
<person name="Zhang J."/>
<person name="Liu J."/>
</authorList>
<dbReference type="PubMed" id="30275017"/>
<dbReference type="DOI" id="10.1074/jbc.ra118.004652"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 258-485 IN COMPLEX WITH RXRA; SYNTHETIC AGONISTS AND NCOA1 PEPTIDE</scope>
<scope>MUTAGENESIS OF ARG-455</scope>
</reference>
<comment type="function">
<text evidence="9 10 13 14 15 16 17 18 19 20 22 23 24 25 26 29 30 31 33 34 35 37 40 43 45 48 49 50 51 55 66 67">Ligand-activated transcription factor. Receptor for bile acids (BAs) such as chenodeoxycholic acid (CDCA), lithocholic acid, deoxycholic acid (DCA) and allocholic acid (ACA). Plays a essential role in BA homeostasis through the regulation of genes involved in BA synthesis, conjugation and enterohepatic circulation. Also regulates lipid and glucose homeostasis and is involved innate immune response (PubMed:10334992, PubMed:10334993, PubMed:21383957, PubMed:22820415). The FXR-RXR heterodimer binds predominantly to farnesoid X receptor response elements (FXREs) containing two inverted repeats of the consensus sequence 5'-AGGTCA-3' in which the monomers are spaced by 1 nucleotide (IR-1) but also to tandem repeat DR1 sites with lower affinity, and can be activated by either FXR or RXR-specific ligands. It is proposed that monomeric nuclear receptors such as NR5A2/LRH-1 bound to coregulatory nuclear responsive element (NRE) halfsites located in close proximity to FXREs modulate transcriptional activity (By similarity). In the liver activates transcription of the corepressor NR0B2 thereby indirectly inhibiting CYP7A1 and CYP8B1 (involved in BA synthesis) implicating at least in part histone demethylase KDM1A resulting in epigenomic repression, and SLC10A1/NTCP (involved in hepatic uptake of conjugated BAs). Activates transcription of the repressor MAFG (involved in regulation of BA synthesis) (By similarity). Activates transcription of SLC27A5/BACS and BAAT (involved in BA conjugation), ABCB11/BSEP (involved in bile salt export) by directly recruiting histone methyltransferase CARM1, and ABCC2/MRP2 (involved in secretion of conjugated BAs) and ABCB4 (involved in secretion of phosphatidylcholine in the small intestine) (PubMed:12754200, PubMed:15471871, PubMed:17895379). Activates transcription of SLC27A5/BACS and BAAT (involved in BA conjugation), ABCB11/BSEP (involved in bile salt export) by directly recruiting histone methyltransferase CARM1, and ABCC2/MRP2 (involved in secretion of conjugated BAs) and ABCB4 (involved in secretion of phosphatidylcholine in the small intestine) (PubMed:10514450, PubMed:15239098, PubMed:16269519). In the intestine activates FGF19 expression and secretion leading to hepatic CYP7A1 repression (PubMed:12815072, PubMed:19085950). The function also involves the coordinated induction of hepatic KLB/beta-klotho expression (By similarity). Regulates transcription of liver UGT2B4 and SULT2A1 involved in BA detoxification; binding to the UGT2B4 promoter seems to imply a monomeric transactivation independent of RXRA (PubMed:12806625, PubMed:16946559). Modulates lipid homeostasis by activating liver NR0B2/SHP-mediated repression of SREBF1 (involved in de novo lipogenesis), expression of PLTP (involved in HDL formation), SCARB1 (involved in HDL hepatic uptake), APOE, APOC1, APOC4, PPARA (involved in beta-oxidation of fatty acids), VLDLR and SDC1 (involved in the hepatic uptake of LDL and IDL remnants), and inhibiting expression of MTTP (involved in VLDL assembly (PubMed:12660231, PubMed:12554753, PubMed:15337761). Increases expression of APOC2 (promoting lipoprotein lipase activity implicated in triglyceride clearance) (PubMed:11579204). Transrepresses APOA1 involving a monomeric competition with NR2A1 for binding to a DR1 element (PubMed:11927623, PubMed:21804189). Also reduces triglyceride clearance by inhibiting expression of ANGPTL3 and APOC3 (both involved in inhibition of lipoprotein lipase) (PubMed:12891557). Involved in glucose homeostasis by modulating hepatic gluconeogenesis through activation of NR0B2/SHP-mediated repression of respective genes. Modulates glycogen synthesis (inducing phosphorylation of glycogen synthase kinase-3) (By similarity). Modulates glucose-stimulated insulin secretion and is involved in insulin resistance (PubMed:20447400). Involved in intestinal innate immunity. Plays a role in protecting the distal small intestine against bacterial overgrowth and preservation of the epithelial barrier (By similarity). Down-regulates inflammatory cytokine expression in several types of immune cells including macrophages and mononuclear cells (PubMed:21242261). Mediates trans-repression of TLR4-induced cytokine expression; the function seems to require its sumoylation and prevents N-CoR nuclear receptor corepressor clearance from target genes such as IL1B and NOS2 (PubMed:19864602). Involved in the TLR9-mediated protective mechanism in intestinal inflammation. Plays an anti-inflammatory role in liver inflammation; proposed to inhibit proinflammatory (but not antiapoptotic) NF-kappa-B signaling) (By similarity).</text>
</comment>
<comment type="function">
<molecule>Isoform 1</molecule>
<text evidence="55">Promotes transcriptional activation of target genes NR0B2/SHP (inducible by unconjugated CDCA), SLC51B/OSTB (inducible by unconjugated CDCA and DCA) and FABP6/IBAP; low activity for ABCB11/BSEP (inducible by unconjugated CDCA, DCA and ACA); not inducible by taurine- and glycine-amidated CDCA.</text>
</comment>
<comment type="function">
<molecule>Isoform 2</molecule>
<text evidence="55">Promotes transcriptional activation of target genes ABCB11/BSEP (inducible by unconjugated CDCA, DCA and ACA), NR0B2/SHP (inducible by unconjugated CDCA DCA and ACA), SLC51B/OSTB (inducible by unconjugated CDCA and DCA) and FABP6/IBAP; not inducible by taurine- and glycine-amidated CDCA.</text>
</comment>
<comment type="function">
<molecule>Isoform 3</molecule>
<text evidence="55">Promotes transcriptional activation of target genes NR0B2/SHP (inducible by unconjugated CDCA), SLC51B/OSTB (inducible by unconjugated CDCA and DCA) and IBAP; low activity for ABCB11/BSEP (inducible by unconjugated CDCA, DCA and ACA); not inducible by taurine- and glycine-amidated CDCA.</text>
</comment>
<comment type="function">
<molecule>Isoform 4</molecule>
<text evidence="55 56">Promotes transcriptional activation of target genes ABCB11/BSEP (inducible by unconjugated CDCA, ACA and DCA), NR0B2/SHP (inducible by unconjugated CDCA, ACA and DCA), SLC51B/OSTB (inducible by unconjugated CDCA and DCA) and FABP6/IBAP; most efficient isoform compared to isoforms 1 to 3; not inducible by taurine- and glycine-amidated CDCA.</text>
</comment>
<comment type="subunit">
<text evidence="9 10 20 21 26 27 28 31 32 35 36 37 41 43 44 45 46 47 53 57">Heterodimer (via C-terminus) with RXRA (via DBD); the heterodimerization enhances the binding affinity for LXXLL motifs from coactivators (PubMed:23462506, PubMed:30275017). Binds DNA predominantly as a heterodimer with RXRA. After activation by agonist binding interacts with coactivators. Interacts with NCOA1, NCOA2, PPARGC1A, CARM1, SETD7, PRMT1, GPS2, SMARCA4 and MED1 (PubMed:15202934, PubMed:14684751, PubMed:15187081, PubMed:15471871, PubMed:15911693, PubMed:17895379, PubMed:18755856, PubMed:19805516, PubMed:23462506, PubMed:12718892, PubMed:12718893, PubMed:18621523, PubMed:18391212, PubMed:19410460, PubMed:19586769). Interacts with EP300 and SMARCD1 (By similarity). Interacts with XRCC5 and XRCC6; decreasing NR1H4/FXR transactivation activity towards ABCB11/BSEP (PubMed:19833092). Interacts with PAGR1 AND NCOA6; indicative for an association with an MLL2/MLL3 complex (ASCOM) (PubMed:19556342).</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1250177">
<id>Q96RI1</id>
</interactant>
<interactant intactId="EBI-455189">
<id>Q15788</id>
<label>NCOA1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1250177">
<id>Q96RI1</id>
</interactant>
<interactant intactId="EBI-1268586">
<id>Q8WTS6</id>
<label>SETD7</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-12417284">
<id>Q96RI1-1</id>
</interactant>
<interactant intactId="EBI-748576">
<id>P28702</id>
<label>RXRB</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>7</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-12417284">
<id>Q96RI1-1</id>
</interactant>
<interactant intactId="EBI-16429492">
<id>P28702-3</id>
<label>RXRB</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-12417284">
<id>Q96RI1-1</id>
</interactant>
<interactant intactId="EBI-712405">
<id>P48443</id>
<label>RXRG</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-9640524">
<id>Q96RI1-2</id>
</interactant>
<interactant intactId="EBI-455189">
<id>Q15788</id>
<label>NCOA1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-9640524">
<id>Q96RI1-2</id>
</interactant>
<interactant intactId="EBI-352053">
<id>P78527</id>
<label>PRKDC</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-10921781">
<id>Q96RI1-3</id>
</interactant>
<interactant intactId="EBI-78473">
<id>P03372</id>
<label>ESR1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location evidence="48">Nucleus</location>
</subcellularLocation>
</comment>
<comment type="subcellular location">
<molecule>Isoform 1</molecule>
<subcellularLocation>
<location evidence="55">Nucleus</location>
</subcellularLocation>
</comment>
<comment type="subcellular location">
<molecule>Isoform 2</molecule>
<subcellularLocation>
<location evidence="55">Nucleus</location>
</subcellularLocation>
</comment>
<comment type="subcellular location">
<molecule>Isoform 3</molecule>
<subcellularLocation>
<location evidence="55">Nucleus</location>
</subcellularLocation>
</comment>
<comment type="subcellular location">
<molecule>Isoform 4</molecule>
<subcellularLocation>
<location evidence="55">Nucleus</location>
</subcellularLocation>
</comment>
<comment type="alternative products">
<event type="alternative promoter"/>
<event type="alternative splicing"/>
<isoform>
<id>Q96RI1-3</id>
<name>1</name>
<name>FXRalpha2(+)</name>
<name>FXRalpha1</name>
<name>FXRbeta1</name>
<sequence type="displayed"/>
</isoform>
<isoform>
<id>Q96RI1-4</id>
<name>2</name>
<name>FXRalpha2(-)</name>
<name>FXRalpha4</name>
<name>FXRbeta2</name>
<sequence type="described" ref="VSP_003665"/>
</isoform>
<isoform>
<id>Q96RI1-1</id>
<name>3</name>
<name>FXRalpha1(+)</name>
<name>FXRalpha1</name>
<sequence type="described" ref="VSP_010135"/>
</isoform>
<isoform>
<id>Q96RI1-2</id>
<name>4</name>
<name>FXRalpha1(-)</name>
<name>FXRalpha2</name>
<sequence type="described" ref="VSP_010135 VSP_003665"/>
</isoform>
<isoform>
<id>Q96RI1-5</id>
<name>5</name>
<sequence type="described" ref="VSP_010135 VSP_044547"/>
</isoform>
</comment>
<comment type="tissue specificity">
<text evidence="42 48 49 55">Liver and hepatocyte-related cells express mainly FXRalpha1-type isoforms with isoform 3 and isoform 4 in approximately equal proportions. In intestine and kidney mainly FXRalpha2-type isoforms are expressed with isoform 1 and isoform 2 in approximately equal proportions. Expressed in pancreatic beta cells and macrophages.</text>
</comment>
<comment type="PTM">
<text evidence="39">Acetylated by EP300. Lys-227 as is the major acetylation site for EP300; the dynamicly regulated acetylation inhibits heterodimerization with RXRA and transactivation activity. Deacetylated by SIRT1.</text>
</comment>
<comment type="PTM">
<text evidence="52">Methylation may increase transactivation of target genes.</text>
</comment>
<comment type="PTM">
<text evidence="39">Phosphorylation by PKC/PRKCA increases transactivation activity by promoting association with PPARGC1A.</text>
</comment>
<comment type="PTM">
<text evidence="48 54">Sumoylated upon ligand binding.</text>
</comment>
<comment type="disease">
<text evidence="63">May be involved in intrahepatic cholestasis of pregnancy.</text>
</comment>
<comment type="disease">
<text evidence="64">May be involved in cholesterol cholelithiasis.</text>
</comment>
<comment type="disease" evidence="56">
<disease id="DI-04774">
<name>Cholestasis, progressive familial intrahepatic, 5</name>
<acronym>PFIC5</acronym>
<description>A disorder characterized by early onset of cholestasis that progresses to hepatic fibrosis, cirrhosis, and end-stage liver disease before adulthood. PFIC5 is an autosomal recessive, severe form characterized by onset of intralobular cholestasis in the neonatal period.</description>
<dbReference type="MIM" id="617049"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="miscellaneous">
<text evidence="68">Ursodeoxycholic (UDCA), a natural agonist of FXR, is approved to treat primary biliary cirrhosis. However, effects are discussed controversial. UDCA is also used to dissolve (cholesterol) gallstones as alternative to surgery.</text>
</comment>
<comment type="miscellaneous">
<molecule>Isoform 1</molecule>
<text>Produced by alternative promoter usage.</text>
</comment>
<comment type="miscellaneous">
<molecule>Isoform 2</molecule>
<text evidence="62">Produced by alternative splicing of isoform 1.</text>
</comment>
<comment type="miscellaneous">
<molecule>Isoform 3</molecule>
<text evidence="62">Produced by alternative promoter usage.</text>
</comment>
<comment type="miscellaneous">
<molecule>Isoform 4</molecule>
<text evidence="62">Produced by alternative splicing of isoform 3.</text>
</comment>
<comment type="miscellaneous">
<molecule>Isoform 5</molecule>
<text evidence="62">Produced by alternative splicing of isoform 3.</text>
</comment>
<comment type="similarity">
<text evidence="62">Belongs to the nuclear hormone receptor family. NR1 subfamily.</text>
</comment>
<comment type="sequence caution" evidence="62">
<conflict type="frameshift">
<sequence resource="EMBL" id="BC144183"/>
</conflict>
</comment>
<comment type="online information" name="Wikipedia">
<link uri="https://en.wikipedia.org/wiki/Farnesoid_X_receptor"/>
<text>Farnesoid X receptor entry</text>
</comment>
<dbReference type="EMBL" id="U68233">
<property type="protein sequence ID" value="AAB08107.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF384555">
<property type="protein sequence ID" value="AAK60271.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF478445">
<property type="protein sequence ID" value="AAM53550.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF478446">
<property type="protein sequence ID" value="AAM53551.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AK296612">
<property type="protein sequence ID" value="BAH12398.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AC010200">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="CH471054">
<property type="protein sequence ID" value="EAW97639.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="BC144183">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BC144184">
<property type="protein sequence ID" value="AAI44185.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BC130573">
<property type="protein sequence ID" value="AAI30574.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS55873.1">
<molecule id="Q96RI1-1"/>
</dbReference>
<dbReference type="CCDS" id="CCDS55874.1">
<molecule id="Q96RI1-5"/>
</dbReference>
<dbReference type="CCDS" id="CCDS55875.1">
<molecule id="Q96RI1-4"/>
</dbReference>
<dbReference type="CCDS" id="CCDS55876.1">
<molecule id="Q96RI1-3"/>
</dbReference>
<dbReference type="CCDS" id="CCDS9078.1">
<molecule id="Q96RI1-2"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001193906.1">
<molecule id="Q96RI1-1"/>
<property type="nucleotide sequence ID" value="NM_001206977.1"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001193907.1">
<molecule id="Q96RI1-5"/>
<property type="nucleotide sequence ID" value="NM_001206978.1"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001193908.1">
<molecule id="Q96RI1-1"/>
<property type="nucleotide sequence ID" value="NM_001206979.1"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001193921.1">
<molecule id="Q96RI1-4"/>
<property type="nucleotide sequence ID" value="NM_001206992.1"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001193922.1">
<molecule id="Q96RI1-3"/>
<property type="nucleotide sequence ID" value="NM_001206993.1"/>
</dbReference>
<dbReference type="RefSeq" id="NP_005114.1">
<molecule id="Q96RI1-2"/>
<property type="nucleotide sequence ID" value="NM_005123.3"/>
</dbReference>
<dbReference type="RefSeq" id="XP_011537342.1">
<molecule id="Q96RI1-1"/>
<property type="nucleotide sequence ID" value="XM_011539040.2"/>
</dbReference>
<dbReference type="PDB" id="1OSH">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.80"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="1OSK">
<property type="method" value="Model"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="3BEJ">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.90"/>
<property type="chains" value="A/B=249-486"/>
</dbReference>
<dbReference type="PDB" id="3DCT">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="A=252-486"/>
</dbReference>
<dbReference type="PDB" id="3DCU">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.95"/>
<property type="chains" value="A=252-486"/>
</dbReference>
<dbReference type="PDB" id="3FLI">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.00"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="3FXV">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.26"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="3GD2">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.20"/>
<property type="chains" value="A=260-486"/>
</dbReference>
<dbReference type="PDB" id="3HC5">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.60"/>
<property type="chains" value="A=257-486"/>
</dbReference>
<dbReference type="PDB" id="3HC6">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.20"/>
<property type="chains" value="A=257-486"/>
</dbReference>
<dbReference type="PDB" id="3L1B">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.90"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="3OKH">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="3OKI">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.00"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="3OLF">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.90"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="3OMK">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.90"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="3OMM">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.10"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="3OOF">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.29"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="3OOK">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.29"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="3P88">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.95"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="3P89">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.30"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="3RUT">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.00"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="3RUU">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="3RVF">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.10"/>
<property type="chains" value="A=257-486"/>
</dbReference>
<dbReference type="PDB" id="4OIV">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.70"/>
<property type="chains" value="A/B=258-483"/>
</dbReference>
<dbReference type="PDB" id="4QE6">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.65"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="4QE8">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.62"/>
<property type="chains" value="A/B=258-486"/>
</dbReference>
<dbReference type="PDB" id="4WVD">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.90"/>
<property type="chains" value="A/B=258-468"/>
</dbReference>
<dbReference type="PDB" id="5IAW">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.58"/>
<property type="chains" value="A/B=259-486"/>
</dbReference>
<dbReference type="PDB" id="5ICK">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.47"/>
<property type="chains" value="A/B=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q0I">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.70"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q0J">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.00"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q0K">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.80"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q0L">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q0M">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.20"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q0N">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.40"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q0O">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.90"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q0P">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.80"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q0Q">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.60"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q0R">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.91"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q0S">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q0T">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.14"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q0U">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.90"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q0V">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.87"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q0W">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.90"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q0X">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.26"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q0Y">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.20"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q0Z">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.26"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q10">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.20"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q11">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.20"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q12">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.00"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q13">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.90"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q14">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.85"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q15">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.90"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q16">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.00"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q17">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.10"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q18">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.90"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q19">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.98"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q1A">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.00"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q1B">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.30"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q1C">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.30"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q1D">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.89"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q1E">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.85"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q1F">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.30"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q1G">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.00"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q1H">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.20"/>
<property type="chains" value="A/C/E/G=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Q1I">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.95"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="5WZX">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.95"/>
<property type="chains" value="A/B=258-485"/>
</dbReference>
<dbReference type="PDB" id="5Y1J">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.00"/>
<property type="chains" value="A=258-485"/>
</dbReference>
<dbReference type="PDB" id="5Y44">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.35"/>
<property type="chains" value="A=258-485"/>
</dbReference>
<dbReference type="PDB" id="5Y49">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.40"/>
<property type="chains" value="A/B=259-485"/>
</dbReference>
<dbReference type="PDB" id="5YXB">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.95"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="5YXD">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.98"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="5YXJ">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.62"/>
<property type="chains" value="A/B=258-486"/>
</dbReference>
<dbReference type="PDB" id="5YXL">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.24"/>
<property type="chains" value="A/C=258-486"/>
</dbReference>
<dbReference type="PDB" id="5Z12">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.75"/>
<property type="chains" value="A/D=259-486"/>
</dbReference>
<dbReference type="PDB" id="6A5W">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.88"/>
<property type="chains" value="A/C=258-485"/>
</dbReference>
<dbReference type="PDB" id="6A5X">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.60"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="6A5Y">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.10"/>
<property type="chains" value="A=258-485"/>
</dbReference>
<dbReference type="PDB" id="6A5Z">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.95"/>
<property type="chains" value="A/H=258-486"/>
</dbReference>
<dbReference type="PDB" id="6A60">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.05"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="6HL0">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.66"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="6HL1">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.60"/>
<property type="chains" value="A=258-486"/>
</dbReference>
<dbReference type="PDB" id="6ITM">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="A/C=257-486"/>
</dbReference>
<dbReference type="PDBsum" id="1OSH"/>
<dbReference type="PDBsum" id="1OSK"/>
<dbReference type="PDBsum" id="3BEJ"/>
<dbReference type="PDBsum" id="3DCT"/>
<dbReference type="PDBsum" id="3DCU"/>
<dbReference type="PDBsum" id="3FLI"/>
<dbReference type="PDBsum" id="3FXV"/>
<dbReference type="PDBsum" id="3GD2"/>
<dbReference type="PDBsum" id="3HC5"/>
<dbReference type="PDBsum" id="3HC6"/>
<dbReference type="PDBsum" id="3L1B"/>
<dbReference type="PDBsum" id="3OKH"/>
<dbReference type="PDBsum" id="3OKI"/>
<dbReference type="PDBsum" id="3OLF"/>
<dbReference type="PDBsum" id="3OMK"/>
<dbReference type="PDBsum" id="3OMM"/>
<dbReference type="PDBsum" id="3OOF"/>
<dbReference type="PDBsum" id="3OOK"/>
<dbReference type="PDBsum" id="3P88"/>
<dbReference type="PDBsum" id="3P89"/>
<dbReference type="PDBsum" id="3RUT"/>
<dbReference type="PDBsum" id="3RUU"/>
<dbReference type="PDBsum" id="3RVF"/>
<dbReference type="PDBsum" id="4OIV"/>
<dbReference type="PDBsum" id="4QE6"/>
<dbReference type="PDBsum" id="4QE8"/>
<dbReference type="PDBsum" id="4WVD"/>
<dbReference type="PDBsum" id="5IAW"/>
<dbReference type="PDBsum" id="5ICK"/>
<dbReference type="PDBsum" id="5Q0I"/>
<dbReference type="PDBsum" id="5Q0J"/>
<dbReference type="PDBsum" id="5Q0K"/>
<dbReference type="PDBsum" id="5Q0L"/>
<dbReference type="PDBsum" id="5Q0M"/>
<dbReference type="PDBsum" id="5Q0N"/>
<dbReference type="PDBsum" id="5Q0O"/>
<dbReference type="PDBsum" id="5Q0P"/>
<dbReference type="PDBsum" id="5Q0Q"/>
<dbReference type="PDBsum" id="5Q0R"/>
<dbReference type="PDBsum" id="5Q0S"/>
<dbReference type="PDBsum" id="5Q0T"/>
<dbReference type="PDBsum" id="5Q0U"/>
<dbReference type="PDBsum" id="5Q0V"/>
<dbReference type="PDBsum" id="5Q0W"/>
<dbReference type="PDBsum" id="5Q0X"/>
<dbReference type="PDBsum" id="5Q0Y"/>
<dbReference type="PDBsum" id="5Q0Z"/>
<dbReference type="PDBsum" id="5Q10"/>
<dbReference type="PDBsum" id="5Q11"/>
<dbReference type="PDBsum" id="5Q12"/>
<dbReference type="PDBsum" id="5Q13"/>
<dbReference type="PDBsum" id="5Q14"/>
<dbReference type="PDBsum" id="5Q15"/>
<dbReference type="PDBsum" id="5Q16"/>
<dbReference type="PDBsum" id="5Q17"/>
<dbReference type="PDBsum" id="5Q18"/>
<dbReference type="PDBsum" id="5Q19"/>
<dbReference type="PDBsum" id="5Q1A"/>
<dbReference type="PDBsum" id="5Q1B"/>
<dbReference type="PDBsum" id="5Q1C"/>
<dbReference type="PDBsum" id="5Q1D"/>
<dbReference type="PDBsum" id="5Q1E"/>
<dbReference type="PDBsum" id="5Q1F"/>
<dbReference type="PDBsum" id="5Q1G"/>
<dbReference type="PDBsum" id="5Q1H"/>
<dbReference type="PDBsum" id="5Q1I"/>
<dbReference type="PDBsum" id="5WZX"/>
<dbReference type="PDBsum" id="5Y1J"/>
<dbReference type="PDBsum" id="5Y44"/>
<dbReference type="PDBsum" id="5Y49"/>
<dbReference type="PDBsum" id="5YXB"/>
<dbReference type="PDBsum" id="5YXD"/>
<dbReference type="PDBsum" id="5YXJ"/>
<dbReference type="PDBsum" id="5YXL"/>
<dbReference type="PDBsum" id="5Z12"/>
<dbReference type="PDBsum" id="6A5W"/>
<dbReference type="PDBsum" id="6A5X"/>
<dbReference type="PDBsum" id="6A5Y"/>
<dbReference type="PDBsum" id="6A5Z"/>
<dbReference type="PDBsum" id="6A60"/>
<dbReference type="PDBsum" id="6HL0"/>
<dbReference type="PDBsum" id="6HL1"/>
<dbReference type="PDBsum" id="6ITM"/>
<dbReference type="SMR" id="Q96RI1"/>
<dbReference type="BioGRID" id="115296">
<property type="interactions" value="26"/>
</dbReference>
<dbReference type="DIP" id="DIP-39370N"/>
<dbReference type="IntAct" id="Q96RI1">
<property type="interactions" value="14"/>
</dbReference>
<dbReference type="STRING" id="9606.ENSP00000447149"/>
<dbReference type="BindingDB" id="Q96RI1"/>
<dbReference type="ChEMBL" id="CHEMBL2047"/>
<dbReference type="DrugBank" id="DB08220">
<property type="generic name" value="(8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid"/>
</dbReference>
<dbReference type="DrugBank" id="DB00132">
<property type="generic name" value="alpha-Linolenic acid"/>
</dbReference>
<dbReference type="DrugBank" id="DB04557">
<property type="generic name" value="Arachidonic Acid"/>
</dbReference>
<dbReference type="DrugBank" id="DB06777">
<property type="generic name" value="Chenodeoxycholic acid"/>
</dbReference>
<dbReference type="DrugBank" id="DB02659">
<property type="generic name" value="Cholic Acid"/>
</dbReference>
<dbReference type="DrugBank" id="DB03619">
<property type="generic name" value="Deoxycholic acid"/>
</dbReference>
<dbReference type="DrugBank" id="DB02509">
<property type="generic name" value="Farnesol"/>
</dbReference>
<dbReference type="DrugBank" id="DB02545">
<property type="generic name" value="Fexaramine"/>
</dbReference>
<dbReference type="DrugBank" id="DB11605">
<property type="generic name" value="Myrrh"/>
</dbReference>
<dbReference type="DrugBank" id="DB05990">
<property type="generic name" value="Obeticholic acid"/>
</dbReference>
<dbReference type="DrugBank" id="DB04348">
<property type="generic name" value="Taurocholic acid"/>
</dbReference>
<dbReference type="DrugBank" id="DB01586">
<property type="generic name" value="Ursodeoxycholic acid"/>
</dbReference>
<dbReference type="DrugCentral" id="Q96RI1"/>
<dbReference type="GuidetoPHARMACOLOGY" id="603"/>
<dbReference type="SwissLipids" id="SLP:000001581"/>
<dbReference type="iPTMnet" id="Q96RI1"/>
<dbReference type="PhosphoSitePlus" id="Q96RI1"/>
<dbReference type="BioMuta" id="NR1H4"/>
<dbReference type="DMDM" id="46577705"/>
<dbReference type="jPOST" id="Q96RI1"/>
<dbReference type="MassIVE" id="Q96RI1"/>
<dbReference type="PaxDb" id="Q96RI1"/>
<dbReference type="PeptideAtlas" id="Q96RI1"/>
<dbReference type="PRIDE" id="Q96RI1"/>
<dbReference type="ProteomicsDB" id="29204"/>
<dbReference type="ProteomicsDB" id="77963">
<molecule id="Q96RI1-3"/>
</dbReference>
<dbReference type="ProteomicsDB" id="77964">
<molecule id="Q96RI1-1"/>
</dbReference>
<dbReference type="ProteomicsDB" id="77965">
<molecule id="Q96RI1-2"/>
</dbReference>
<dbReference type="ProteomicsDB" id="77966">
<molecule id="Q96RI1-4"/>
</dbReference>
<dbReference type="Antibodypedia" id="17868">
<property type="antibodies" value="429 antibodies"/>
</dbReference>
<dbReference type="DNASU" id="9971"/>
<dbReference type="Ensembl" id="ENST00000188403">
<molecule id="Q96RI1-4"/>
<property type="protein sequence ID" value="ENSP00000188403"/>
<property type="gene ID" value="ENSG00000012504"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000392986">
<molecule id="Q96RI1-1"/>
<property type="protein sequence ID" value="ENSP00000376712"/>
<property type="gene ID" value="ENSG00000012504"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000548884">
<molecule id="Q96RI1-2"/>
<property type="protein sequence ID" value="ENSP00000448506"/>
<property type="gene ID" value="ENSG00000012504"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000549996">
<molecule id="Q96RI1-5"/>
<property type="protein sequence ID" value="ENSP00000448978"/>
<property type="gene ID" value="ENSG00000012504"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000551379">
<molecule id="Q96RI1-3"/>
<property type="protein sequence ID" value="ENSP00000447149"/>
<property type="gene ID" value="ENSG00000012504"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000648861">
<molecule id="Q96RI1-1"/>
<property type="protein sequence ID" value="ENSP00000496908"/>
<property type="gene ID" value="ENSG00000012504"/>
</dbReference>
<dbReference type="GeneID" id="9971"/>
<dbReference type="KEGG" id="hsa:9971"/>
<dbReference type="UCSC" id="uc001thp.3">
<molecule id="Q96RI1-3"/>
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="9971"/>
<dbReference type="DisGeNET" id="9971"/>
<dbReference type="EuPathDB" id="HostDB:ENSG00000012504.13"/>
<dbReference type="GeneCards" id="NR1H4"/>
<dbReference type="HGNC" id="HGNC:7967">
<property type="gene designation" value="NR1H4"/>
</dbReference>
<dbReference type="HPA" id="ENSG00000012504">
<property type="expression patterns" value="Tissue enriched (liver)"/>
</dbReference>
<dbReference type="MalaCards" id="NR1H4"/>
<dbReference type="MIM" id="603826">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="MIM" id="617049">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="neXtProt" id="NX_Q96RI1"/>
<dbReference type="OpenTargets" id="ENSG00000012504"/>
<dbReference type="Orphanet" id="69665">
<property type="disease" value="Intrahepatic cholestasis of pregnancy"/>
</dbReference>
<dbReference type="Orphanet" id="480476">
<property type="disease" value="Progressive familial intrahepatic cholestasis type 5"/>
</dbReference>
<dbReference type="PharmGKB" id="PA31752"/>
<dbReference type="eggNOG" id="KOG3575">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00940000158037"/>
<dbReference type="HOGENOM" id="CLU_007368_12_3_1"/>
<dbReference type="InParanoid" id="Q96RI1"/>
<dbReference type="KO" id="K08537"/>
<dbReference type="OMA" id="IPSETFF"/>
<dbReference type="OrthoDB" id="1137281at2759"/>
<dbReference type="PhylomeDB" id="Q96RI1"/>
<dbReference type="TreeFam" id="TF316304"/>
<dbReference type="PathwayCommons" id="Q96RI1"/>
<dbReference type="Reactome" id="R-HSA-159418">
<property type="pathway name" value="Recycling of bile acids and salts"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-192105">
<property type="pathway name" value="Synthesis of bile acids and bile salts"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-193368">
<property type="pathway name" value="Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-193807">
<property type="pathway name" value="Synthesis of bile acids and bile salts via 27-hydroxycholesterol"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1989781">
<property type="pathway name" value="PPARA activates gene expression"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-211976">
<property type="pathway name" value="Endogenous sterols"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-383280">
<property type="pathway name" value="Nuclear Receptor transcription pathway"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-4090294">
<molecule id="Q96RI1-2"/>
<property type="pathway name" value="SUMOylation of intracellular receptors"/>
</dbReference>
<dbReference type="SignaLink" id="Q96RI1"/>
<dbReference type="SIGNOR" id="Q96RI1"/>
<dbReference type="BioGRID-ORCS" id="9971">
<property type="hits" value="3 hits in 891 CRISPR screens"/>
</dbReference>
<dbReference type="ChiTaRS" id="NR1H4">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="EvolutionaryTrace" id="Q96RI1"/>
<dbReference type="GeneWiki" id="Farnesoid_X_receptor"/>
<dbReference type="GenomeRNAi" id="9971"/>
<dbReference type="Pharos" id="Q96RI1">
<property type="development level" value="Tclin"/>
</dbReference>
<dbReference type="PRO" id="PR:Q96RI1"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 12"/>
</dbReference>
<dbReference type="RNAct" id="Q96RI1">
<property type="molecule type" value="protein"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000012504">
<property type="expression patterns" value="Expressed in right lobe of liver and 114 other tissues"/>
</dbReference>
<dbReference type="ExpressionAtlas" id="Q96RI1">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="Q96RI1">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0042025">
<property type="term" value="C:host cell nucleus"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="InterPro"/>
</dbReference>
<dbReference type="GO" id="GO:0000790">
<property type="term" value="C:nuclear chromatin"/>
<property type="evidence" value="ECO:0000247"/>
<property type="project" value="NTNU_SB"/>
</dbReference>
<dbReference type="GO" id="GO:0005719">
<property type="term" value="C:nuclear euchromatin"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005654">
<property type="term" value="C:nucleoplasm"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0043235">
<property type="term" value="C:receptor complex"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0090575">
<property type="term" value="C:RNA polymerase II transcription regulator complex"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0032052">
<property type="term" value="F:bile acid binding"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0038181">
<property type="term" value="F:bile acid receptor activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1902122">
<property type="term" value="F:chenodeoxycholic acid binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0001228">
<property type="term" value="F:DNA-binding transcription activator activity, RNA polymerase II-specific"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0003700">
<property type="term" value="F:DNA-binding transcription factor activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="GO" id="GO:0000981">
<property type="term" value="F:DNA-binding transcription factor activity, RNA polymerase II-specific"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0004879">
<property type="term" value="F:nuclear receptor activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ParkinsonsUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0016922">
<property type="term" value="F:nuclear receptor binding"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0046965">
<property type="term" value="F:retinoid X receptor binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0000978">
<property type="term" value="F:RNA polymerase II cis-regulatory region sequence-specific DNA binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0000977">
<property type="term" value="F:RNA polymerase II transcription regulatory region sequence-specific DNA binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ParkinsonsUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0043565">
<property type="term" value="F:sequence-specific DNA binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0038023">
<property type="term" value="F:signaling receptor activity"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0008134">
<property type="term" value="F:transcription factor binding"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0000976">
<property type="term" value="F:transcription regulatory region sequence-specific DNA binding"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008270">
<property type="term" value="F:zinc ion binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="InterPro"/>
</dbReference>
<dbReference type="GO" id="GO:0015721">
<property type="term" value="P:bile acid and bile salt transport"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0008206">
<property type="term" value="P:bile acid metabolic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0038183">
<property type="term" value="P:bile acid signaling pathway"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0030154">
<property type="term" value="P:cell differentiation"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0007043">
<property type="term" value="P:cell-cell junction assembly"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0001678">
<property type="term" value="P:cellular glucose homeostasis"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:1903413">
<property type="term" value="P:cellular response to bile acid"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0071398">
<property type="term" value="P:cellular response to fatty acid"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0071222">
<property type="term" value="P:cellular response to lipopolysaccharide"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0071417">
<property type="term" value="P:cellular response to organonitrogen compound"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0035356">
<property type="term" value="P:cellular triglyceride homeostasis"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042632">
<property type="term" value="P:cholesterol homeostasis"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0042742">
<property type="term" value="P:defense response to bacterium"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0055089">
<property type="term" value="P:fatty acid homeostasis"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0034971">
<property type="term" value="P:histone H3-R17 methylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006954">
<property type="term" value="P:inflammatory response"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0045087">
<property type="term" value="P:innate immune response"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0032620">
<property type="term" value="P:interleukin-17 production"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0038185">
<property type="term" value="P:intracellular bile acid receptor signaling pathway"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0030522">
<property type="term" value="P:intracellular receptor signaling pathway"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0055088">
<property type="term" value="P:lipid homeostasis"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0006629">
<property type="term" value="P:lipid metabolic process"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0043066">
<property type="term" value="P:negative regulation of apoptotic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043124">
<property type="term" value="P:negative regulation of I-kappaB kinase/NF-kappaB signaling"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0050728">
<property type="term" value="P:negative regulation of inflammatory response"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0032689">
<property type="term" value="P:negative regulation of interferon-gamma production"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0032692">
<property type="term" value="P:negative regulation of interleukin-1 production"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0032703">
<property type="term" value="P:negative regulation of interleukin-2 production"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0032715">
<property type="term" value="P:negative regulation of interleukin-6 production"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0071638">
<property type="term" value="P:negative regulation of monocyte chemotactic protein-1 production"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0032088">
<property type="term" value="P:negative regulation of NF-kappaB transcription factor activity"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0000122">
<property type="term" value="P:negative regulation of transcription by RNA polymerase II"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:1904468">
<property type="term" value="P:negative regulation of tumor necrosis factor secretion"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0010804">
<property type="term" value="P:negative regulation of tumor necrosis factor-mediated signaling pathway"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0010903">
<property type="term" value="P:negative regulation of very-low-density lipoprotein particle remodeling"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0001080">
<property type="term" value="P:nitrogen catabolite activation of transcription from RNA polymerase II promoter"/>
<property type="evidence" value="ECO:0000305"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0007219">
<property type="term" value="P:Notch signaling pathway"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:1904179">
<property type="term" value="P:positive regulation of adipose tissue development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:2001250">
<property type="term" value="P:positive regulation of ammonia assimilation cycle"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:2000213">
<property type="term" value="P:positive regulation of glutamate metabolic process"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0046628">
<property type="term" value="P:positive regulation of insulin receptor signaling pathway"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0035774">
<property type="term" value="P:positive regulation of insulin secretion involved in cellular response to glucose stimulus"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:1905695">
<property type="term" value="P:positive regulation of phosphatidic acid biosynthetic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ParkinsonsUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0045944">
<property type="term" value="P:positive regulation of transcription by RNA polymerase II"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ParkinsonsUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0070857">
<property type="term" value="P:regulation of bile acid biosynthetic process"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0090181">
<property type="term" value="P:regulation of cholesterol metabolic process"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0061178">
<property type="term" value="P:regulation of insulin secretion involved in cellular response to glucose stimulus"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0010988">
<property type="term" value="P:regulation of low-density lipoprotein particle clearance"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006357">
<property type="term" value="P:regulation of transcription by RNA polymerase II"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006355">
<property type="term" value="P:regulation of transcription, DNA-templated"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0034255">
<property type="term" value="P:regulation of urea metabolic process"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0034142">
<property type="term" value="P:toll-like receptor 4 signaling pathway"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0034162">
<property type="term" value="P:toll-like receptor 9 signaling pathway"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0006367">
<property type="term" value="P:transcription initiation from RNA polymerase II promoter"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="DisProt" id="DP01914"/>
<dbReference type="Gene3D" id="1.10.565.10">
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Gene3D" id="3.30.50.10">
<property type="match status" value="1"/>
</dbReference>
<dbReference type="IDEAL" id="IID00391"/>
<dbReference type="InterPro" id="IPR035500">
<property type="entry name" value="NHR-like_dom_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR000536">
<property type="entry name" value="Nucl_hrmn_rcpt_lig-bd"/>
</dbReference>
<dbReference type="InterPro" id="IPR001723">
<property type="entry name" value="Nuclear_hrmn_rcpt"/>
</dbReference>
<dbReference type="InterPro" id="IPR001728">
<property type="entry name" value="ThyrH_rcpt"/>
</dbReference>
<dbReference type="InterPro" id="IPR001628">
<property type="entry name" value="Znf_hrmn_rcpt"/>
</dbReference>
<dbReference type="InterPro" id="IPR013088">
<property type="entry name" value="Znf_NHR/GATA"/>
</dbReference>
<dbReference type="Pfam" id="PF00104">
<property type="entry name" value="Hormone_recep"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF00105">
<property type="entry name" value="zf-C4"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PRINTS" id="PR00398">
<property type="entry name" value="STRDHORMONER"/>
</dbReference>
<dbReference type="PRINTS" id="PR00047">
<property type="entry name" value="STROIDFINGER"/>
</dbReference>
<dbReference type="PRINTS" id="PR00546">
<property type="entry name" value="THYROIDHORMR"/>
</dbReference>
<dbReference type="SMART" id="SM00430">
<property type="entry name" value="HOLI"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00399">
<property type="entry name" value="ZnF_C4"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF48508">
<property type="entry name" value="SSF48508"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS51843">
<property type="entry name" value="NR_LBD"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00031">
<property type="entry name" value="NUCLEAR_REC_DBD_1"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS51030">
<property type="entry name" value="NUCLEAR_REC_DBD_2"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0007">Acetylation</keyword>
<keyword id="KW-0010">Activator</keyword>
<keyword id="KW-0877">Alternative promoter usage</keyword>
<keyword id="KW-0025">Alternative splicing</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-0238">DNA-binding</keyword>
<keyword id="KW-0391">Immunity</keyword>
<keyword id="KW-0395">Inflammatory response</keyword>
<keyword id="KW-0399">Innate immunity</keyword>
<keyword id="KW-0988">Intrahepatic cholestasis</keyword>
<keyword id="KW-1017">Isopeptide bond</keyword>
<keyword id="KW-0479">Metal-binding</keyword>
<keyword id="KW-0488">Methylation</keyword>
<keyword id="KW-0539">Nucleus</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0675">Receptor</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0678">Repressor</keyword>
<keyword id="KW-0804">Transcription</keyword>
<keyword id="KW-0805">Transcription regulation</keyword>
<keyword id="KW-0832">Ubl conjugation</keyword>
<keyword id="KW-0862">Zinc</keyword>
<keyword id="KW-0863">Zinc-finger</keyword>
<feature type="chain" description="Bile acid receptor" id="PRO_0000053538">
<location>
<begin position="1"/>
<end position="486"/>
</location>
</feature>
<feature type="domain" description="NR LBD" evidence="12">
<location>
<begin position="262"/>
<end position="486"/>
</location>
</feature>
<feature type="DNA-binding region" description="Nuclear receptor" evidence="11">
<location>
<begin position="134"/>
<end position="209"/>
</location>
</feature>
<feature type="zinc finger region" description="NR C4-type" evidence="11">
<location>
<begin position="137"/>
<end position="157"/>
</location>
</feature>
<feature type="zinc finger region" description="NR C4-type" evidence="11">
<location>
<begin position="173"/>
<end position="197"/>
</location>
</feature>
<feature type="region of interest" description="Agonist binding" evidence="10">
<location>
<begin position="342"/>
<end position="350"/>
</location>
</feature>
<feature type="binding site" description="Agonist" evidence="10">
<location>
<position position="375"/>
</location>
</feature>
<feature type="binding site" description="Agonist" evidence="10">
<location>
<position position="383"/>
</location>
</feature>
<feature type="binding site" description="Agonist" evidence="10">
<location>
<position position="461"/>
</location>
</feature>
<feature type="binding site" description="Agonist" evidence="10">
<location>
<position position="483"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by PKC/PRKCA" evidence="39">
<location>
<position position="145"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by PKC/PRKCA" evidence="39">
<location>
<position position="164"/>
</location>
</feature>
<feature type="modified residue" description="N6-acetyllysine; by EP300">
<location>
<position position="167"/>
</location>
</feature>
<feature type="modified residue" description="N6-methyllysine; by SETD7" evidence="52">
<location>
<position position="220"/>
</location>
</feature>
<feature type="modified residue" description="N6-acetyllysine; by EP300">
<location>
<position position="227"/>
</location>
</feature>
<feature type="modified residue" description="Phosphothreonine; by PKC/PRKCZ" evidence="65">
<location>
<position position="456"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1)" evidence="69">
<location>
<position position="132"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1)" evidence="69">
<location>
<position position="289"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 3, isoform 4 and isoform 5." id="VSP_010135" evidence="59 60 61">
<original>MVMQFQGLENPIQISPHCSCTPSGFFMEMMSMKPAK</original>
<variation>MGSKMNLIEHSHLPTTDEFSFSENLF</variation>
<location>
<begin position="1"/>
<end position="36"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 5." id="VSP_044547" evidence="59">
<location>
<begin position="159"/>
<end position="209"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 2 and isoform 4." id="VSP_003665" evidence="58 61">
<location>
<begin position="207"/>
<end position="210"/>
</location>
</feature>
<feature type="sequence variant" description="In PFIC5; loss of isoform 4 transcription regulatory region sequence-specific DNA binding activity; loss of isoform 4 function in regulation of transcription DNA-templated." id="VAR_077017" evidence="56">
<original>Y</original>
<variation>YK</variation>
<location>
<position position="149"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abrogates SUMO1-mediated inhibition of ligand-induced transcactivation at ABCB11/BSEP and NR0B2/SHP promoters; when associated with R-289 and A-291." evidence="54">
<original>K</original>
<variation>R</variation>
<location>
<position position="132"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreases transcriptional activation SLC51A/OSTA, SLC51B/OSTB and ABCB11/BSEP, no effect on interaction with RXRA and SETD7." evidence="53">
<original>K</original>
<variation>R</variation>
<location>
<position position="132"/>
</location>
</feature>
<feature type="mutagenesis site" description="Impairs ligand-dependent transactivation activity, impairs interaction with PPARGC1A; when associated with A-164." evidence="39">
<original>S</original>
<variation>A</variation>
<location>
<position position="145"/>
</location>
</feature>
<feature type="mutagenesis site" description="Impairs ligand-dependent transactivation activity, impairs interaction with PPARGC1A; when associated with A-145." evidence="39">
<original>S</original>
<variation>A</variation>
<location>
<position position="164"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreases transcriptional activation of SLC51B/OSTB, no effect on SLC51A/OSTA and ABCB11/BSEP, no effect on interaction with RXRA and SETD7." evidence="53">
<original>K</original>
<variation>R</variation>
<location>
<position position="167"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreases transcriptional activation of SLC51B/OSTB, no effect on SLC51A/OSTA and ABCB11/BSEP, impairs interaction with RXRA and SETD7." evidence="53">
<original>K</original>
<variation>R</variation>
<location>
<position position="220"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreases transcriptional activation SC51A/OSTA, SLC51B/OSTB and ABCB11/BSEP, impairs interaction with RXRA and enhances interaction with SETD7, decreases association with ABCB11/BSEP promoter." evidence="53">
<original>K</original>
<variation>R</variation>
<location>
<position position="227"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abrogates SUMO1-mediated inhibition of ligand-induced transcactivation at ABCB11/BSEP and NR0B2/SHP promoters; when associated with R-132 and A-291." evidence="54">
<original>K</original>
<variation>R</variation>
<location>
<position position="289"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abrogates SUMO1-mediated inhibition of ligand-induced transcactivation at ABCB11/BSEP and NR0B2/SHP promoters; when associated with R-132 and R-289." evidence="54">
<original>E</original>
<variation>A</variation>
<location>
<position position="291"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreases transcriptional activation SLC51A/OSTA, SLC51B/OSTB and ABCB11/BSEP, no effect on interaction with RXRA and SETD7, decreases association with ABCB11/BSEP promoter." evidence="53">
<original>K</original>
<variation>R</variation>
<location>
<position position="353"/>
</location>
</feature>
<feature type="mutagenesis site" description="As a heterodimer with RXRA, impaired transcriptional activity." evidence="57">
<original>R</original>
<variation>S</variation>
<location>
<position position="455"/>
</location>
</feature>
<feature type="mutagenesis site" description="Impairs transcriptional activation of ABCB11/BSEP." evidence="38">
<original>T</original>
<variation>A</variation>
<location>
<position position="456"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreases transcriptional activation SLC51A/OSTA, SLC51B/OSTB and ABCB11/BSEP, no effect on interaction with RXRA and impairs interaction with SETD7." evidence="53">
<original>K</original>
<variation>R</variation>
<location>
<position position="474"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 7; AAI44185." ref="7" evidence="62">
<original>K</original>
<variation>R</variation>
<location>
<position position="198"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 7; BC144183." ref="7" evidence="62">
<original>C</original>
<variation>V</variation>
<location>
<position position="217"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="261"/>
<end position="274"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="281"/>
<end position="289"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="294"/>
<end position="317"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="322"/>
<end position="324"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="327"/>
<end position="349"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="350"/>
<end position="353"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="354"/>
<end position="356"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="357"/>
<end position="359"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="360"/>
<end position="367"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="369"/>
<end position="371"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="373"/>
<end position="387"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="388"/>
<end position="390"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="393"/>
<end position="404"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="409"/>
<end position="411"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="415"/>
<end position="436"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="438"/>
<end position="440"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="443"/>
<end position="465"/>
</location>
</feature>
<feature type="helix" evidence="7">
<location>
<begin position="470"/>
<end position="472"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="477"/>
<end position="483"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4OIV"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5Q0I"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5Y49"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5YXD"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000244">
<source>
<dbReference type="PDB" id="6A5X"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000244">
<source>
<dbReference type="PDB" id="6A5Y"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000244">
<source>
<dbReference type="PDB" id="6HL0"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000244">
<source>
<dbReference type="PDB" id="6HL1"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="Q60641"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="Q62735"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00407"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU01189"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10334992"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10334993"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10514450"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11579204"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11927623"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12554753"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12660231"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12718892"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12718893"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12754200"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12806625"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12815072"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12891557"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14684751"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15187081"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15202934"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15239098"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15337761"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15471871"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15911693"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16269519"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16946559"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17895379"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18391212"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18621523"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18668687"/>
</source>
</evidence>
<evidence key="39" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18755856"/>
</source>
</evidence>
<evidence key="40" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19085950"/>
</source>
</evidence>
<evidence key="41" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19159286"/>
</source>
</evidence>
<evidence key="42" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19393742"/>
</source>
</evidence>
<evidence key="43" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19410460"/>
</source>
</evidence>
<evidence key="44" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19556342"/>
</source>
</evidence>
<evidence key="45" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19586769"/>
</source>
</evidence>
<evidence key="46" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19805516"/>
</source>
</evidence>
<evidence key="47" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19833092"/>
</source>
</evidence>
<evidence key="48" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19864602"/>
</source>
</evidence>
<evidence key="49" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20447400"/>
</source>
</evidence>
<evidence key="50" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21242261"/>
</source>
</evidence>
<evidence key="51" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21804189"/>
</source>
</evidence>
<evidence key="52" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22345554"/>
</source>
</evidence>
<evidence key="53" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23462506"/>
</source>
</evidence>
<evidence key="54" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23546875"/>
</source>
</evidence>
<evidence key="55" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23928191"/>
</source>
</evidence>
<evidence key="56" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="26888176"/>
</source>
</evidence>
<evidence key="57" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="30275017"/>
</source>
</evidence>
<evidence key="58" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="12062799"/>
</source>
</evidence>
<evidence key="59" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="15489334"/>
</source>
</evidence>
<evidence key="60" type="ECO:0000303">
<source ref="1"/>
</evidence>
<evidence key="61" type="ECO:0000303">
<source ref="2"/>
</evidence>
<evidence key="62" type="ECO:0000305"/>
<evidence key="63" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="17681172"/>
</source>
</evidence>
<evidence key="64" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="17931734"/>
</source>
</evidence>
<evidence key="65" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="18668687"/>
</source>
</evidence>
<evidence key="66" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="21383957"/>
</source>
</evidence>
<evidence key="67" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="22820415"/>
</source>
</evidence>
<evidence key="68" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="23235576"/>
</source>
</evidence>
<evidence key="69" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="23546875"/>
</source>
</evidence>
<sequence length="486" mass="55914" checksum="C23283576A8CF76B" modified="2004-04-26" version="2">MVMQFQGLENPIQISPHCSCTPSGFFMEMMSMKPAKGVLTEQVAGPLGQNLEVEPYSQYSNVQFPQVQPQISSSSYYSNLGFYPQQPEEWYSPGIYELRRMPAETLYQGETEVAEMPVTKKPRMGASAGRIKGDELCVVCGDRASGYHYNALTCEGCKGFFRRSITKNAVYKCKNGGNCVMDMYMRRKCQECRLRKCKEMGMLAECMYTGLLTEIQCKSKRLRKNVKQHADQTVNEDSEGRDLRQVTSTTKSCREKTELTPDQQTLLHFIMDSYNKQRMPQEITNKILKEEFSAEENFLILTEMATNHVQVLVEFTKKLPGFQTLDHEDQIALLKGSAVEAMFLRSAEIFNKKLPSGHSDLLEERIRNSGISDEYITPMFSFYKSIGELKMTQEEYALLTAIVILSPDRQYIKDREAVEKLQEPLLDVLQKLCKIHQPENPQHFACLLGRLTELRTFNHHHAEMLMSWRVNDHKFTPLLCEIWDVQ</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution (CC BY 4.0) License
</copyright>
</uniprot>

